WO 2006/069153 PCT/DS2005/046360
VITAMIN D RECEPTOR MODULATORS
REFERENCE TO RELATED APPLICATION
This application claims the benefit of priority under title 35 United States Code §
119(e) of Provisional Patent Application No. 60/637,930 filed December 21, 2004, which
is incorporated herein by reference in its entirety
BACKGROUND OF THE INVENTION
Vitamin D Receptor (VDR) is a ligand dependent transcription factor that belongs
to the superfamily of nuclear hormone receptors. The VDR protein is 427 amino acids,
with a molecular weight of -50 kDa. The VDR ligand, la,25-dihydroxyvitamin D3 (the
hormonally active form of Vitamin D) has its action mediated by its interaction with the
nuclear receptor known as Vitamin D receptor ("VDR"). The VDR ligand, lα,.25-
dihydroxyvitamin D3 (lα,25(OH)2D3) acts upon a wide variety of tissues and cells both
related to and unrelated to calcium and phosphate homeostasis.
The activity of lα,25-dihydroxyvitamin D3 in various systems suggests wide
clinical applications. However, use of conventional VDR ligands is hampered by their
associated toxicity, namely hypercalcemia (elevated serum calcium). Currently,
1α,25(OH)2D3, marketed as Rocaltrol® pharmaceutical agent ( product of Hoffmann-La
Roche), is administered to kidney failure patients undergoing chronic kidney dialysis to
treat hypocalcemia and the resultant metabolic bone disease. Other therapeutic agents,
such as Calcipotriol® (synthetic analog of lα,25(OH)2D3 ) show increased separation of
binding affinity on VDR from hypercalcemic activity.
Chemical modifications of lα,25(OH)2D3 have yielded analogs with attenuated
calcium mobilization effects (R. Bouillon et. al., Endocrine Rev. 1995, 16, 200-257). One
such analog, Dovonex ® pharmaceutical agent (product of Bristol-Meyers Squibb Co.), is
currently used in Europe and the United States as a topical treatment for mild to moderate
psoriasis (K. Rragballe et. al., Br. J. Dermatol. 1988,119, 223-230).
2

WO 2006/069153 PCT/DS2005/046360
Other Vitamin D3 mimics have been described in the publication, Vitamin D
Analogs: Mechanism of Action of Therapeutic Applications, by Nagpal, S.; Lu, J.;
Boehm, M. F., Curr. Med. Chem. 2001, 8,1661-1679.
Although some degree of separation between the beneficial action and calcium
raising (calcemic) effects has been achieved with these VDR ligands, to date the
separation has been insufficient to allow for oral administration to treat conditions such as
osteoporosis, cancers, leukemias, and severe psoriasis.
One example of a major class of disorder that could benefit from VDR mediated
biological efficacy in the absence of hypercalcemia is osteoporosis. Osteoporosis is a
systemic disorder characterized by decreased bone mass and microarchitectural
deterioration of bone tissue leading to bone fragility and increased susceptibility to
fractures of the hip, spine, and wrist (World Health Organization WHO 1994).
Osteoporosis affects an estimated 75 million people in the United States, Europe, and
Japan.
Within the past few years, several antiresorptive therapies have been introduced.
These include bisphosphonates, hormone replacement therapy (HRT), a selective
estrogen receptor modulator (SERM), and calcitonins. These treatments reduce bone
resorption, bone formation, and increase bone density. However, none of these
treatments increase true bone volume nor can they restore lost bone architecture.
Another major disorder that could benefit from VDR mediated biological activity
is psoriasis. Psoriasis is one of the most common dermatologic diseases and is a chronic
inflammatory skin condition characterized by erythematous, sharply demarcated papules
and rounded plaques, covered by silvery micaceous scale.
Synthetic VDR ligands with reduced calcemic potential have been synthesized.
For example, a class of bis-phenyl compounds stated to mimic lα, 25-dihydroxyvitamin
D3 is described in US Patent No. 6,218,430 and the article; "Novel nonsecosteroidal
vitamin D mimics exert VDR-modulating activities with less calcium mobilization than
lα, 25-Dihydroxyvitamin D3'' by Marcus F. Boehm, et. al., Chemistry & Biology 1999,
Vol 6, No. 5, pgs. 265-275.
Synthetic VDR ligands having an aryl-thiophene nucleus are described in
United States provisional patent application SN 60/384,151, filed 29 May 2002 (WO

WO 2006/069153 PCT/DS2005/046360
03/101,978), and synthetic VDR ligands having phenyl-benzoxazole nucleus are
described in United States provisional patent application SN 60/638,029 filed 21
December 2004.
There remains a need for improved treatments using alternative or improved
pharmaceutical agents that mimic la, 25-dihydroxyvitamin D3 to stimulate bone
formation, restore bone quality, and treat other diseases without the attendant
disadvantage of hypercalcemia.
SUMMARY OF THE INVENTION
Novel compounds having a phenyl-naphthalene nucleus of Formula "(PN)" have
been found effective as Vitamin D Receptor modulators (VDRM):

wherein the variables R, R', RP, RP3, Lp1, Lp2, Zp, RN,, LNP, and ZNP are as hereinafter
defined.
In another aspect, the present invention is directed towards pharmaceutical
compositions containing pharmaceutically effective amounts of compounds of Formula I
4

WO 2006/069153 PCT/DS2005/046360
or a pharmaceutically acceptable salt or a prodrug thereof, either singly or in
combination, together with pharmaceutically acceptable carriers and/or auxiliary agents.
Another aspect of the invention is a pharmaceutical formulation for treatment or
prevention of osteoporosis containing pharmaceutically effective amounts of the vitamin
D receptor modulator compound of Formula I alone or together with pharmaceutically
effective amounts of co-agents conventionally used for the treatment of osteoporosis.
Another aspect of the invention is a pharmaceutical formulation for treatment or
prevention of psoriasis containing pharmaceutically effective amounts of the vitamin D
receptor modulator compound of Formula I alone or together with pharmaceutically
effective amounts of co-agents conventionally used for the treatment of psoriasis.
Another aspect of the invention is a pharmaceutical formulation for treatment or
prevention of prostate cancer containing pharmaceutically effective amounts of the
vitamin D receptor modulator compound of Formula I alone or together with
pharmaceutically effective amounts of co-agents conventionally used for the treatment of
prostate cancer.
Another aspect of the invention is to use the compounds of Formula I to treat
disease states responsive to Vitamin D receptor ligands.
Another aspect of the invention is the prevention and treatment of acne, actinic
keratosis, alopecia, Alzheimer's disease, autoimmune induced diabetes, benign prostatic
hyperplasia, bladder cancer, bone fracture healing, breast cancer, Crohn's disease,
prostate cancer, colon cancer, Type I diabetes, host-graft rejection, hypercalceimia, Type
II diabetes, leukemia, multiple sclerosis, insufficient sebum secretion, osteomalacia,
osteoporosis, insufficient dermal firmness, insufficient dermal hydration, myelodysplastic
syndrome, psoriatic arthritis, psoriasis, renal osteodystrophy, rheumatoid arthritis,
scleroderma, seborrheic dermatitis, skin cancer, systemic lupus erythematosis, skin cell
damage from mustard vesicants,' ulcerative colitis, and wrinkles, by administering to a
mammal in need thereof a pharmaceutically effective amount of a compound of Formula
I.
DETAILED DESCRIPTION OF THE INVENTION
Definitions:
5

WO 2006/069153 PCT/DS2005/046360
The term, "abscess" refers to adverse complications often associated with surgery,
trauma, or diseases that predispose the host to abscess formation from encapsulated
bacteria lymphocytes, macrophages, and etc.
The term, "adhesion" refers to the adverse and abnormal union of surfaces
normally separate by the formation of new fibrous tissue resulting from an inflammatory
process.
The term, "compound of the invention" refers to a compound represented by
Formula I or as set out as products of the Examples or synthesis schemes described
herein.
The term, "Active Ingredient" means a compound of the invention.
6
The term, "mustard" is inclusive of both sulfur mustards and nitrogen mustards,
either alone or in any combination. Exemplary of such compounds are the vesicants;
bis(2-chloroethyl) sulfide (Chemical Agent Symbol HD), C1(CH2)2S(CH2)2C1 1,2-
bis(2-chloroethylthio)ethane (Chemical Agent Symbol Q), C1(CH2)2S(CH2)2S(CH2)2C1;
bis(2-chloroethylthioethyl) ether, C1(CH2)2S(CH2)O(CH2)2S(CH2)2C1 (Chemical Agent
Symbol T); tris(2-chloroethyl) amine (Chemical Agent Symbol HN3) N(CH2CH2C1)3;
N-methyl-2,2'-dichlorodietliylamine (Chemical Agent Symbol NH2); and 2,2'-
dichlorotriethylamine, CH3CH2N(CH2CH2C1)2 (Chemical Agent Symbol NH1).
The term heteroaryl as used herein refers to the heteroaryls illustrated below:


7
WO 2006/069153 PCT/DS2005/046360


WO 2006/069153 PCT/DS2005/046360
where the dotted line crossing a solid line symbol represents a bond of attachment
between the atom of the radical and the rest of the molecule.
The term, "(Acidic Group)" means an organic group that acts as a proton donor
capable of hydrogen bonding. Illustrative of an (Acidic Group) is a group selected from
the following: carboxylic acid, acylsulfonamide, tetrazolyl, substituted heteroaryls with
acidic hydrogens, i.e., hydroxyl groups.
The term, "mammal" includes humans.
The terms "halo" and halogen refer to fluorine, chlorine, bromine, and iodine.
. Preferred halogens for the present invention include fluorine.
Unless specified herein, chemical terms are used in their customary usage as
understood by one skilled in the art.
The term, "C1-3 alky!" refers to an alkyl group selected from methyl, ethyl, n-
propyl, and isopropyl. The abbreviations, "Me" means methyl; "Et" means ethyl; "iPr" or
"i-Pr'T means 1-methylethyl; and "tBu" or "t-Bu" means 1,1-dimethylethyl.
The term, "branched C3-C5 alkyl" is an alkyl group selected from 1-methylethyl;
1-methylpropyl; 2-methylpropyl; 1,1-dimethylethyl; 1,1-dimethylpropyl; 1,2-
dimethylpropyl; or 2,2-dimethylpropyl. Preferred branched C3-C5 alkyl groups are 2-
methylpropyl and 1,1-dimethylethyl, with the 1,1-dimethylethyl group being most
preferred.
The term "alkenyl" refers to aliphatic groups wherein the point of attachment is a
carbon-carbon double bond, for example vinyl, 1-propenyl, and 1-cyclohexenyl. Alkenyl
groups may be straight-chain, branched-chain, cyclic, or combinations thereof, and may
be optionally substituted. It will be understood that alkenyl groups can include one or
more double bonds. Further, the alkenyl groups can include positional isomers about the
double bonds i.e. trans (Z) or cis (E) isomers. Suitable alkenyl groups have from 2 to
about 20 carbon atoms. It also will be understood by those skilled in the art that
compounds of the present invention can exist in two or more tautomeric forms. All such
tautomeric forms are contemplated to be included within the scope of the present
invention.
The term "C1-C5 alkyl" refers to saturated aliphatic groups including straight-
chain, branched-chain, and cyclic groups and any combinations thereof. Examples of C1-
8

WO 2006/069153 PCT/DS2005/046360
C5 alkyl groups are methyl, ethyl, n-propyl, from 1-methylethyl; n-butyl, 1-methylpropyl;
2-methylpropyl; l,l-dimethylethyl;n-amyl, 1,1-dimethylpropyl; 1,2-dimethylpropyl; and
2,2-dimethylpropyl.
The term "cycloalkyl" includes organic radicals having 3 to 8 carbon atoms as
ring members. Examples include: cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
When substituted, the substituents can be selected from halo, hydroxyl, -CN, C1-C3 alkyl,
-SH, -OC1-C3 alkyl, and -SC1-C3 alkyl.
The term, "cycloalkenyl" includes organic radicals having 3 to 8 carbon atoms as
ring members; non-limiting examples include: cyclopropenyl, cyclobutenyl,
cyclopentenyl and cyclohexenyl.
The term, "C4-C5 haloalkyl" is an alkyl group containing one or more halogen
atoms. The term, "C1-C5 fluoroalkyl" is an alkyl group containing fluorine and includes
organic radicals such as -CF3, -CHF2, -CH2F, -CF2CF3, -CHFCF3, -CH2CF3,
-CH2CHF2, and -CH2CH2F, with -CF3 being preferred.
The term, "hydroxyalkyl" means an alkyl group having at least one hydroxyl
group. Non-limiting examples include: 3-methyl-3-hydroxypentyl, 3-methyl-3-
hydroxypentenyl, 3-methyl-3-hydroxypentynyl, 3-ethyl-3-hydroxypentyl, 3-ethyl-3-
hydroxypentenyl, 3-ethyl-3-hydroxypentynyl, 3-ethyl-3-hydroxy-4-methylpentyl, 3-ethyl-
3-hydroxy-4-methylpentenyl, 3-ethyl-3-hydroxy-4-methylpentynyl, 3-propyl-3-
hydroxypentyl, 3-propyl-3-hydroxypentenyl, 3-propyl-3-hydroxypentynyl, l-hydroxy-2-
methyl-l-(methylethyl)propyl, 2-methyl-3-hydroxy-4,4-dimethylpentyl, 2-methyl-3-
hydroxy-3-ethylpentyl, 2-ethyl-3-hydroxy-3-ethylpentyl, 2-ethyl-3-hydroxy-4,4-
dimethylpentyl, 1-hydroxycycloalkenyl; and 1-hydroxycycloalkyl.
The term "hydroxycycloalkyl" refers to a radical having the general structural
formula:

where w is an integer from 1 to 6 and the hydroxyl radical is substituted on any ring
carbon atom. Examples include: 2-hydroxycyclohexylmethyl, 3-methyl-2-
9

WO 2006/069153 PCT/DS2005/046360
hydroxyeyclohexyloxy, 3-methyl-2-hydroxycyclohexylmethyl, and 3,3-dimethyl -2-
hydroxycyclohexyloxy.
The terra "1-hydroxycycloalkyl" refers to a radical having the general structural
formula:

where w is defined as above. Examples of 1-hydroxycycloalkyl radicals include: 1-
hydroxycyclopropyl, 1-hydroxycyclobutyl, 1-hydroxycyclopentyl, 1-hydroxycyclohexyl,
1-hydroxycycloheptyl, and 1-hydroxycyclooctyl.
The term oxocycloalkyl refers to a radical having the general structural formula:

where w is defined as above. The bond of attachment of the oxocycloalkyl to the
referenced molecule need not be restricted to the carbon adjacent to the carbonyl carbon,
but can be attached via any of the carbon atoms making up the rings. Non-limiting
examples of oxocycloalkyl radicals include: 2-oxocyclohexyloxy, 2-
oxocyclohexylmethyl, 3-methyl-2-oxocyclohexyloxy, 3-methyl-2-oxocyclohexylmethyl,
3,3-dimethyl-2-oxocyclohexyloxy, 3,3-dimethyl-2-oxocyclohexylmethyl, and 2-
hydroxycyclohexyloxy.
Certain compounds of the invention exist in isomeric configurations with chiral
centers, i.e., diastereomers and enatiomers. Each of the isomeric forms of the compounds
is contemplated to be within the scope of the present invention. Each of the various
isomers can be prepared as single isomers and/or separated into single isomers by
techniques known to those skilled in the art. Therefore, the compounds of the present
invention can be used either as single isomer or isomeric form or alternatively the
compounds of the present invention can be used as a combination of isomers. The
10

WO 2006/069153 PCT/DS2005/046360
"jagged" bond illustrated below is used to represent that carbon to which it is attached can
exist as either configuration, i.e., R or S.

It also will be understood by those skilled in the art that compounds of the present
invention can exist in two or more tautomeric forms. All such tautomeric forms are
contemplated to be included within the scope of the present invention.
Compounds of the Invention:
The compounds of the invention with vitamin receptor modulating (VDRM)
activity are represented by Formula (I) or a pharmaceutically acceptable salt or a prodrug
derivative thereof:

wherein
R and R' are independently C4-C5 alkyl, C4-C5 haloalkyl, or together R and R'
form a substituted or unsubstituted, saturated or unsaturated cycloalkyl ring having from
3 to 8 carbon atoms;
RP3 and RN are independently selected from the group consisting of hydrogen,
halo, C1-C5 alkyl, C4-C5 haloalkyl, -O-C1-C5 alkyl, -S-C1-C5 alkyl, -O-C1-C5
haloalkyl, -CN, -NO2, acetyl, -S-C1-C5 haloalkyl, C2-C5 alkenyl, C3-C5 cycloalkyl,
and C3-C5 cycloalkenyl;
11

WO 2006/069153 PCT/DS2005/046360
RP is selected from: hydrogen, halo, C1-C5 alkyl, C4-C5 haloalkyl, -O-C1-C5
alkyl, -S-C1-C5 alkyl, -O-C1-C5 haloalkyl, -CN, -NO2, acetyl, -S-C1-C5 haloalkyl,
C2-C5 alkenyl, C3-C5 cycloalkyl, and C3-C5 cycloalkenyl;
(Lpi), (Lp2), and (LNP) are divalent linking groups independently selected from the
group consisting of: a bond, -(CH2)m-C(OH)-, -(CH2)m-O-, -(CH2)m-S-, -(CH2)m-S(O)-,
-(CH2)m-S(O)2-, -(CH2)m-N(R40)-, -(CH2)m-C(R40)(R41)-, -(CH2)m-C(O)-,
-N(R40)-C(O)-, -(CH2)m-CH=CH-, and -(CH2)m-OC-;
where m is 0-5;
R40 and R41 each is independently selected from: hydrogen, C1-C5 alkyl, C1-
C5 hydroxyalkyl, C1-C5 haloalkyl, C2-C5 alkenyl, C3-C5 cycloalkyl, C3-C5
cycloalkenyl;
Zp is selected from: branched C3-C5 alkyl, C3-C10 hydroxyalkyl, C3-C10
hydroxyalkenyl, C3-C10hydroxyalkynyl, C3-C10hydroxycycloalkyl, C4-C10hydroxy
cycloalkenyl, and oxocycloalkyl;
ZNP is selected from: C1-C5 alkyl, C2-C5 alkenyl, C3-C5 cycloalkyl,
C3-C5 cycloalkenyl, C1-C5 hydroxyalkyl, C1-C5 haloalkyl, C1-C5 alkylaryl,
C1-C5hydroxyalkylaryl, Co-C5 alkyl-CO2H, C0-C3 alkyl-cycloalkyl-CO2H, C0-C5
alkyl-N(R40)(R41), -X-(Ci-C5 alkyl), -X-(C,-C5 alkenyl), -X-(C3-C5 cycloalkyl),
-X-(C3-C5 cycloalkenyl), -X-(CrC5 haloalkyl), -X-(CrC5 hydroxyalkyl), -X-(C,-C5
alkylaryl), -X(OCrC5 alkyl), -XN(R40)(R41), -XN(R40)aryl, -N(CH3)(OCH3),
-N(OH)(CH3), -N(R42)-(CrC5 alkyl)CO2H, -N(R42)-(Ci-C5 alkyl)C(O)(Ci-C5 alkyl),
-N(R42)-(Ci-C5 alkyl)C(O)(OCi-C5 alkyl), -N(R42)-SO2-(C1-C5 alkyl),
-NR(42)-S(O)-(Ci-C5 alkyl), -P(O)-(OC!-C5 alkyl)2, heteroaryl, and
-N=C(R40)N(R40)(R41);
R42 is selected from: H, C1-C3 alkyl, and Ci-C3 haloalkyl; and
X is selected from: O,C(O), C(S), S(O), and SO2;
provided that -(LNP)-ZNP is substituted at either the 12 or 13 position of the
naphthalene ring; or
a pharmaceutically acceptable salt, solvate, prodrug, enantiomer, racemate,
diastereomer or mixture of diastereomers thereof.
12

WO 2006/069153 PCT/DS2005/046360
It will be understood by those skilled in the art that the individual groups listed
herein for the divalent linkers, (LP1), (LP2), and (LNP), can be attached at either end to the
benzoxazole nucleus. For example, for the linker, -N(R40)-C(O)-, either the nitrogen can
be attached to the naphthalene nucleus or alternatively the carbonyl carbon can be
attached to the naphthalene nucleus.
In preferred embodiments, compounds of the invention include the compound of
Formula I having as preferred substituents;
R and R' are independently methyl or ethyl;
RP is hydrogen or methyl;
RP3 and RN are independently hydrogen, methyl, ethyl, -O-methyl, or
cyclopropyl;
(Lp1) is a bond;
(Lp2) is a bond, -CH2-, -CH(OH)-, or -C(Me)OH-;
(LNP) is a bond, -C(O)-, -C(O)NH-, or -C(0)N(Me)-;
Zp is 1,1-dimethylethyl, 1-hydroxycyclopentyl, 1-hydroxycyclohexyl, 3-efhyl-3-
hydroxypentyl, 3-ethyl-3-hydroxypentenyl, or 3-ethyl-3-hydroxypentynyl,
ZNP is -CO2H, -CO2(R40), -N(R40)(R41), -NH-C(Me)(OH)-C(O)OH,
-C(O)NMe~CH2-C(O)OH, -C(O)NMe-CH2-C(O)OMe, -C(O)NMe-CH2-C(O)OEt,
-C(O)NMe-CH2-C(O)OiPr, -C(O)NMe-CH2-C(O)tBu, -cyclopropyl-C(O)OH,
-cyclobutyl-C(O)OH, -C(O)NMe-C(Me)2-C(O)OH, -C(O)N(R40)S(O)(R42),
-C(O)N(R40)SO2R42, -C(O)-N(R40)-5-tetrazolyl,
-C(O)N(R40)-(C1-C5 alkyl)-S(O)R42, -C(O)N(R40)-(C|-C5 alkyl)-S(O)2R42,
C0-C3 alkyl(cycloalkyl)C(O)NHSO2Me, Co-C3 alkyl-(cycloalkyl)-C(O)OH, C0-C3
alkyl-(cycloalkyl)-C(O)NH-heteroaryl, C0-C3 alkyl-(cycloalkyl)-NHSO2(C1-C5 alkyl),
and -CH2CO2H.
Preferred compounds of the invention and salts and prodrug derivatives are
represented by formulae Cl to C8 as follows:
13


WO 2006/069153 PCT/DS2005/046360
14

WO 2006/069153 PCT/DS2005/046360

where Rl is H, Me, or Et; R2 is H or Me, R3 is H Me, or Et; and R4 is H or Me.
Particularly preferred compounds include compounds represented by formulae C1-C8
where Rl is a Me or Et; and R2 and R3 individually are H or Me.
EXAMPLES
General Experimental Conditions:
The starting material/intermediate is the compound from the immediate preceding
experimental unless otherwise indicated.
All reactions are performed under nitrogen/argon atmosphere, in a stirred reaction
vessel, and at room temperature unless indicated otherwise.
Unless otherwise indicated, the notation that "organic layer is MgSO4/Na2SO4
dried" " dryed over MgSO4/Na2SO4- is defined as swirling or stirring the solution with a
15

WO 2006/069153 PCT/DS2005/046360
dessicant (MgSO4 and/or Na2SO4) 5-15 ra, then filtering off the dessicant to give an
anhydrous filtrate.
For analogous multi-step reaction procedures, the yield is given either for the
ultimate step or overall multi-steps as indicated.
Solutions are "concentrated" at a range of 25-75 °C with reduced pressure (0.05 to
1 mm).
Unless otherwise indicated, "the residue is chromatographed" is defined as silica
gel chromatography of residue with moderate nitrogen pressure (flash chromatography)
or a medium pressure chromatography systems using a silica gel to crude product ratio of
-10-100.
For HPLC, the conditions listed are for the analytical trace only. For Preparative
HPLC, the eluent is similar to analytical HPLC eluent.
Thin layer chromatography is performed with silica gel plates with UV and/or
appropriate staining solution.
NMR spectra are obtained with either 300 or 400 mHz spectrometer. NMR data
is listed to denote spectrum is consistent with assigned structure. "NMR" notation
without data denotes spectrum is consistent with assigned structure.
HRMS - high resolution mass spectrum
ES-MS - electrospray mass spectrum
Abbreviations:
Aq - aqueous
d-day
eq - equivalent
h - hour
m - minute
satd - saturated
disp - dispersion
quant - quantitative
rt for retention time (both small caps to minimize confusion with RT)
RT - room temperature
16

WO 2006/069153 PCT/DS2005/046360

TABLE 1
Chemical Terms
Term Definition Term Definition
BF3-OEt2 boron trifluoride etherate MeOH methanol
BnBr benzyl bromide NMO 4-raethylmorpholine
N-oxide
CH2C12 Dichloromethane NMP N-methylpyrrolidin-
2-one
DMAP 4-(dimethylamino)pyridine Na-S-R3 sodium
alkylmercaptide
DMF N,N-dimethylformamide PBr3 phosphorus
tribromide
DMSO Dimethylsulfoxide Pd(DPPF) palladium
dichloro[l,l'-
bis(diphenylphosphi
no)ferrocene
DPPB 1,4-bis(diphenylphosphino) Pd(OAc)2 palladium (II)
butane acetate
DPPF dichloro[l,l'- Pd(TPP)4 palladium
bis(diphenylphosphino) tetrakistriphenylphos
ferrocene phine
EDCI 3-Ethyl-1 -[3-(dimethylamino) Pd-C palladium on carbon
propy 1] carbodiimide
hydrochloride
EEDC Diethyl cyanamide Pd-C/H2 palladium on carbon
17

WO 2006/069153 PCT/DS2005/046360

Term Definition Term Definition
with hydrogen
pressure
EtMgBr ethyl magnesium bromide pTSA para-toluenesulfonic
acid
EtOAc ethyl acetate Pyr pyridine
EtOH Ethanol Red-Al sodium bis(2-
methoxyethoxy)alu
minum hydride
H2 hydrogen pressure R2MgBr alkyl magnesium
bromide
H2NCH2CO methyl glycinate R3MgBr alkyl magnesium
2Me bromide
Hept Heptane R5MgBr alkyl magnesium
bromide
Hex Hexanes R3S(O)2C1 alkylsulfonyl
chloride
HN(OMe)Me N-methyl-O-methyl R2S(O)2N alkylsulfonamide
hydroxylamine H2
HNMe2 dimethyl amine TBSC1 tert-buty 1 dimethy
lsilyl chloride
HATU O-(7-azabenzotriazol-1 -y I)- tBuC(O)C 1 -bromopinacolone
N,N,N',N'-tetramethyl H2Br-
uronium hexafluorophosphate
HOAT 7-aza-l-hydroxy benzotriazole Tf2O triflic anhydride
18

WO 2006/069153 PCT/DS2005/046360

Term Definition Term Definition
HOBT 1 -hydr oxybenzotr iazole TFA trifluoroacetic acid
K2CO3 potassium carbonate THF tetrahydrofuran
LAH Lithium aluminum hydride Ti(OiPr)4 titanium
tetraisopropoxide
LDA Lithium diisopropyl amide
LiHMDS Lithium hexamethyl disilazide TMS- trimethylsilyl
acetylene acetylene
Lindlar Pd-CaCO3-PbO TPAP tetrapropylammoniu
catalyst m perruthenate
mCPBA meta-chloroperbenzoic acid BnHalide benzylhalide
TPA 12-0-tetradecanoyl 13-acetate PHA Phytohemagglutinin
(Sigma) (Sigma)
NaHMDS Sodium hexamethyl disilazide
NMM N-methylmorpholine
19

20
WO 2006/069153 PCT/DS2005/046360


WO 2006/069153 PCT/DS2005/046360
6-Hydroxy-2-naphthoic acid is esterified in an alkanol with acid catalysis
(HC1, sulfuric acid, or toluenesulfonic acid) from room temperature to the reflux
temperature of the mixture to give the ester 1. Ester 1 is protected, e.g., with a
benzylhalide and base to give the protected ester 2. Ester 2 is treated with excess alkyl
Grignard reagent (2 to 5 equivalents) in diethylether or THF from 0 ° C. to room
temperature to give the tert-carbinol 3. Carbinol 3 is hydrogenated with a catalyst,
e.g., palladium on carbon to give the deprotected carbinol 4. Carbinol 4 is reacted
with triflic anhydride to produce the triflate that dehydrates upon work up to the Z/E-
olefin 5. Triflate 5 is reacted with carbon monoxide (1 to 100 psi) and a palladium
catalyst (0.1 to 10%) in alkanol with DMF from room temperature to 150 ° C. for 8 to
48 h to give the ester 6. Ester 6 alkylates an ortho-substituted phenol in the presence
of a Lewis acid, e.g., boron trifluoride etherate (0.01 to 5 equivalents) at room
temperature to give the diarylmethane 7. A variety ortho-substitued phenols are
commercially available or can be readily prepared by those skilled in the art. The free
hydroxyl of the diarylmethane 7 is alkylated with an alpha-halo ketone (z-
C(O)CH2hal, where z is an alkyl group or a substituted alkyl group) to give keto ester
8. Keto ester 8 is saponified with lithium, sodium, or potassium hydroxide in alkanol
from room temperature to the relux temperature of the mixture to give the keto acid 9.
Keto acid 9 is reduce to the carbinol 10. with lithium or sodium borohydride, or
cyanoborohydride in alkanol at room temperature.
21

22
WO 2006/069153 PCT/DS2005/046360


WO 2006/069153 PCT/DS2005/046360
Scheme II.
2,7-Dihydroxynaphthalene is reacted with triflic anhydride (0.9 to 1.3
equivalents) to produce the mono-triflate 11. Triflate 11 is reacted with carbon
monoxide (1-100 psi) in DMF with alkanol and a palladium catalyst from room
temperature to 150 ° C. and from 8 to 48 h to give the ester 12. The ester 12 is
protected, e.g., with a benzylhalide and base to give the protected ester 13. Ester 13 is
reacted with an excess of alkyl Grignard reagent (2-5 equivalents) to give the tert-
carbinol 14. The protection group of 14 is removed, e.g., by hydrogenation in alkanol
with a palladium catalyst to give the unprotected tert-carbinol 15. Carbinol 15 is
converted to triflate 16. with triflic anhydride and base. Triflate 16 is converted to the
ester 17 as above with carbon monoxide in DMF/alkanol and base in the presence of a
palladium catalyst, e.g., palladium acetate and DPPB. Ester 17 alkylates an ortho-
substituted phenol in the presence of a Lewis acid, e.g., boron trifluoride etherate
(0.01 to 5 equivalents) at room temperature to give the diarylmethane 18. The free
hydroxyl of the diarylmethane 18 is alkylated with an alpha-halo ketone(z-
C(O)CH2hal, where z is an alkyl group or a substituted alkyl group) to give keto ester
19. Keto ester 19 is saponified with lithium, sodium, or potassium hydroxide in
alkanol from room temperature to the reflux temperature of the mixture to give the
keto acid 20. Reduction of keto acid 20 to the carbinol is achieved as above with
lithium or sodium borohydride or cyanoborohydride in alkanol at room temperature.
Each of the free acids produced in each of the above schemes (9, 10, and 20)
are converted to esters and carboxamides using reactions well known to those skilled
in the art.
23

WO 2006/069153 PCT/DS2005/046360

Alcohol 17 is reacted with BF3-OEt2 and o-cresol (or another ortho
substituted phenol) to give phenol 21. Phenol 21 is reacted with an alpha haloketone
(z-C(O)CH2hal, where z is an alkyl group or a substituted alkyl group) and a base to
give ketone 22. Ketone 22 is treated with a hindered base (LDA or NaHMDS) and
either methyl halide or ethyl halide (or other alkyl halide) to afford ketone 23. Ketone
23 is reacted with an alkali hydroxide to give acid 24. Acid 24 is coupled with
substituted amino acid ester using EDCI/HOBT/NMM (N-methylmorpholine) to
amide-ester 26. Coupling of acid 24 with cyclic amino acid ester the corresponding
cyclic amide-ester 26 is obtained. Amide-ester 26 is reacted with alkali hydroxide to
give amide 27.
24

25
WO 2006/069153 PCT/DS2005/046360


WO 2006/069153 PCT/DS2005/046360
Scheme IV.
Ketone-acid 24 is reacted with NaBH4/MeOH to give alcohol-acid 28. Alcohol-
acid 28 is coupled with substituted sulfonamide using EDCI/DMAP to afford
acylsulfonamide 29. Alcohol-acid 28 is reacted with EDCI/5-aminotetrazole/DMAP to
give acylaminotetrazole 30. (The 5-aminotetrazole can be replaced with other
heterocyclics or heteroaryl groups as desired.) Alcohol-acid 28 is reacted with
formamide and NaOMe at 100 °C to produce amide 31. Amide 31 is reacted with Et3N,
2-chloro-l,3-dimethylimidazolinium hexafluorophosphate, and TFA to afford nirrile 32.
Nitrile 32 is reacted with Bu3SnN3 at 80 °C to give tetrazole 33.
Example 1. Preparation of 6-{ l-[4-(3,3-dimemyl-2-oxobutoxy)-3-methylphenyl]-l-
ethylpropyl} naphthalene-2-carboxylic acid

Treat a mixture of 6-hydroxy-2-naphthoic acid (4.45g, 23.6 mmol) in 2,2-
dimethoxypropane (235 mL) with cone. HC1 (24 mL) and then MeOH (60 niL). Stir
tlie reaction at RT for 16 h and then at 55 °C for 16 h. Pour the reaction mixture into
EtOAc (250 mL) and wash with brine (3 x 100 mL). Dry the organic layer over
Na2SO4, concentrate the filtrate, and chromatograph the concentrated filtrate (0.5 kg
silica gel, 5:95 to 15:85 EtOAc:hex) to give the title compound (4.77 g, quant). MS
(ES) m/e 203 (M+l).
26

WO 2006/069153 PCT/DS2005/046360

Treat 6-hydroxynaphthalene-2-carboxylic acid methyl ester (4.77 g, 23.6
mmol) and benzyl bromide (3.3 mL, 28.3 mmol) in DMF (22 mL) with cesium
carbonate (15.3 g, 47.2 mmol). Stir the mixture for 22 h at RT and concentrate.
Dilute the concentrate with EtOAc (300 mL) and water (100 mL). Wash the organic
layer with brine (3 x 100 mL), dry it over Na2SO4, and filter. Concentrate the filtrate.
Purifiy the product using medium pressure silica gel chromatography (15:85 to 50:50
EtOAc:hex) to give the title compound as a white solid (5.75 g, 83%). MS (ES) m/e
293 (M+l).

Cool 6-benzyloxynaphthalene-2-carboxylic acid methyl ester (5.75 g, 19.67
mmol) in THF (115 mL) to about 0 °C and treat the solution dropwise with ethyl
magnesium bromide (23.0 mL, 69.0 mmol, 3.0 M in ether). Allow the reaction to
warm to RT and stir it for 3 h. Quench with water and concentrate. Dissolve the
crude residue in CH2CL2 (200 mL), wash twice with brine, dry over Na2SO4 and
filter. Concentrate the filtrate to give the title compound as a yellow solid (6.0 g,
95%). MS (ES) m/e 321 (M+l).
D. 6-(l -Ethyl-1 -hydroxypropyl)naphthalen-2-ol
27

WO 2006/069153 PCT/DS2005/046360

Treat a mixture of 3-(6-benzyloxynaphthalen-2-yl)pentan-3-ol (1.5 g, 4.68
nunol) and 5% Pd/A12CO3 (0.90 g) in ethanol (750 mL) with hydrogen at 60 psi for 8
h at RT. Filter the catalyst from the reaction mixture and concentrate the filtrate to
give the title compound as a yellow solid (0.94 g, 87%). MS (ES) m/e 229 (M-l).

Cool a solution of 6-(l -ethyl- l-hydroxypropyl)naphthalen-2-ol (0.94 g, 4.08
mmol) and pyridine (1.3 mL, 16.3 mmol) in CH2CL2 (30 mL) in an ice bath and treat
dropwise with trifluoromethanesulfonic anhydride (1.0 mL, 6.1 mmol). Remove the
cooling bath, and stir the mixture at RT for lh. Quench the reaction mixture with ice
water. Dilute the mixture with CH2CL2 (80 mL), wash twice with brine, dry over
Na2SO4 and filter. Concentrate the filtrate and purify by silica gel radial
chromatography (CH2CL2) to give the title compound as a yellow oil (0.93 g, 66%).
MS (ES) m/e 361 (M+NH4).

Treat a mixture containing trifluoromethanesulfonic acid 6-(l-
ethylpropenyl)naphthalen-2-yl ester (0.92 g, 2.67 mmol), Pd(OAc)2 (0.020 mg, 0.09
28

WO 2006/069153 PCT/DS2005/046360
mmol), tis-(diphenylphosphino)ferrocene (0.046 g, 0.083 mmol), Et3N (0.67 mL,
4.81 nunol), in MeOH (10 mL) and DMSO (15 mL) with carbon monoxide at 100 psi
at 80 °C for 4 h. Pour the reaction mixture into ether (100 mL) and wash the mixture
with brine (4 x 50 mL). Dilute the organic layer with EtOAc (100 mL), wash with
brine, then dry over Na2SO4 and filter. Concentrate the filtrate to give the title
compound as an off-white solid (0.67 g, quant). MS (ES) m/e 255 (M+l).

29
Cool a solution of 6-(l-ethyl-propenyl)naphthalene-2-carboxylic acid methyl
ester (0.74 g, 2.75 mmol) and o-cresol (2.0 mL, 19.4 mmol) in CH2CL2 (20 mL) to
-78 °C; dropwise add BF3-OEt2 (1.22 mL, 9.6 mmol). Remove the cooling bath and
stir the reaction at RT for 16 h. Quench the reaction with ice water; then dilute with
EtOAc (200 mL). Wash the resulting mixture twice with brine, dry over Na2SO4,
filter, and concentrate the filtrate. Purify the product using medium pressure silica gel
chromatography (100% hex to 25:75 EtOAc:hex) to give the title compound as, a
white solid (0.87 g, 87%). MS (ES) m/e 363 (M+l).


WO 2006/069153 PCT/DS2005/046360
1-bromopinacolone (0.64 g, 3.60 mmol), and potassium carbonate (1.0 g, 7.2 mmol)
in acetone (15 mL) at RT for 16 h. Concentrate the reaction mixture and dilute the the
residue with EtOAc (100 mL) and water (50 mL). Adjust the pH of the mixture to 1
using 1 N HC1. Discard the aqueous layer and wash the organic layerwith brine, dry
over Na2SO4, then filter. Concentrate the Filtrate and purify by silica gel radial
chromatography (5:95 EtOAc:hex to 15:85 EtoAc:hex) to give the title compound as
an off-white solid (0.53 g, 48%). MS (ES) m/e 461 (M+l).

30
Treat a solution of 6-{ l-[4-(3,3-Dimethyl-2-oxobutoxy)-3-methylphenyl]-l-
ethylpropyl}-naphthalene-2-carboxylic acid methyl ester (0.53 g, 1.15 mmol) in THF
(8 mL) and MeOH (16 mL) with 2N NaOH (2.9 mL, 5.8 mmol) and heat at 55 °C for
16 h. Concentrate the reaction mixture. Dilute the residue with in EtOAc (50 mL)
and water (25 mL) and acidify the residing mixture to pH 1 using IN HC1. Discard
the aqueous layer and wash the organic layer with brine, Dry the organic layer over
Na2SO4, filter, and concentrate the filtrate to give the title compound as a yellow
solid (0.45 g, 87%) . MS (ES) m/e 447 (M+l).


WO 2006/069153 PCT/DS2005/046360
Treat a solution of 6-{l-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-l-
ethylpropyl}naphthalene-2-carboxylic acid (0.15 g, 0.34 mmol) in THF (6 mL) with
NaBH4 (0.025 g, 0.67 mmol) and stir the reaction mixture at RT for 1 h. Quench the
reaction first with water (5 mL) and then with IN HC1 (2 mL). Remove the THF
under vacuum. Dilute the mixture with EtOAc (50 mL), wash with brine (2x), dry
over NaSO4 and filter. Concentrate the filtrate to give the title compound (0.15 g).
MS(ES)m/e447(M-l).

Chromatograph a mixture of racemic 6-{ l-ethyl-l-[4-(2-hydroxy-3,3-
dimethyl-butoxy)-3-methyl-phenyl]-propyl}-naphthalene-2-carboxylic acid (2.93 g)
on a Chiralpak AD-H column, Daicel Chemical Industries, to give enantiomer 1,
Example 2A (1.42 g, 48%) and enantiomer 2, Example 2B (1.38 g, 47%).
Enantiomer 1, Example 2A.
HPLC: ChiralPak AD-H (4.6x150); 60%heptane/40%IPA/0.1%TFA; 0.6
mL/m (flow rate); uv. 250 nm.
rt= 10 m
Enantiomer 2, Example 2B
HPLC: ChiralPak AD-H (4.6x150); 60%heptane/40%DPA/0.1%TFA; 0.60
mL/m (flow rate); uv. 250 nm.
rt=16m
31

WO 2006/069153 PCT/DS2005/046360

32
Treat a solution of 6-{ l-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-l-
ethylpropyl)naphthalene-2-carboxylic acid (0.11 g, 0.246 mmol) in CH2CL2 (1.0
rnL) dropwise with oxalyl chloride (0.13 mL, 1.48 mmol). Stir the solution at RT for
1 h and concentrate to give 6-{ l-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-l-
ethylpropyl}naphthalene-2-carbonyl chloride ("the acid chloride")- Treat a mixture of
methylglycine HC1 (0.031 g, 0.25 mmol) and EON (0.51 mL, 0.37 mmol) in CH2CL2
(3 mL) with a solution of the acid chloride (0.057 g, 0.123 mmol) in CH2CL2 (1 mL).
Stir the reaction at RT for 16 h and concentrate. Dissolve the residue in THF (0.5
mL) and MeOH (1.0 mL) and treat with 2N NaOH (0.24 mL, 0.48 mmol). Heat the
solution to 50 °C for 16 h, concentrate, dilute with CH2CL2 and water (10 mL each).
Acidify the resulting mixture to pH 1 using 5N HC1. Wash the organic layer with
brine, dry over Na2SO4, and filter. Concentrate the filtrate and purify by silica gel
radial chromatography (10:90 MeOH:CH2CL2) to give the title compound as a white
solid (0.021 g, 34%). MS (ES) m/e 504 (M+l).


WO 2006/069153 PCT/DS2005/046360
Et3N (0.034 mL, 0.25 mmol) in CH2CL2 (3 mL) with 6-{ l-[4-(3,3-dimethyl-2-
oxobutoxy)-3-methylphenyl]-l-ethylpropyl}naphthalene-2-carbonyl chloride (0.057
g, 0.123 mmol) in CH2CL2 (1 mL). Stir the mixture at RT for 16 h; dilute with
CH2CL2 and water. Acidify the resulting mixture to pH 1 using 5N HC1. Separate
the organic layer from the aqueous layer. Wash the oganic layer with brine, dry over
Na2SO4, and filter. Concentrate the filtrate to give the title compound as a yellow
solid (0.033 g, 57%). MS (ES) m/e 474 (M+l).

ethylpropyl}naphthalene-2-carboxylic acid (0.10 g, 0.222 mmol), sarcosine ethyl ester
HC1 (0.069 g, 0.45 mmol), DMAP (0.108 g, 0.89 mmol) and EEDC (0.086 g, 0.45
mmol) in CH2CL2 (2 mL). Stir the mixture at RT for 16 h. Dilute the reaction
mixture with CH2CL2 and water. Acidify to pH 1 using IN HC1. Separate and
disgard the the aqueous layer. Wash the organic layer with brine, dry over Na2SO4,
and filter. Concentrate the filtrate and purify by silica gel radial chromatography
(25:75 EtOAcrhex to 50:50 EtoAc:hex) to give the title compound as a white solid
(0.093 g, 78%). MS (ES) m/e 546 (M+l).
33

WO 2006/069153 PCT/DS2005/046360
B. [(6-{ l-[4-(3,3-Dimethyl-2-oxobutoxy)-3-methylphenyl]-l-
ethylpropyl} naphthalene-2-carbonyl)methylamino]acetic acid
Treat a solution of [(6-{l-[4-(3,3-Dimethyl-2-oxobutoxy)-3-methylpheayl]-l-
eihylpropyl}naphthalene-2-carbonyl)methylamino] acetic acid ethyl ester (0.090 g,
0.16 mmol) in THF (1.25 mL) and EtOH (2.5 mL) with 2N NaOH (0.80 mL, 1.6
nunol). Heat the mixture to 50 °C for 16 h. Acidify the reaction mixture to pH 1
using IN HC1. Concentrate the resulting mixture. Dilute the residue with EtOA.c and
water (25 mL each). Separate and discard the aqueous layer. Wash the organic layer
with brine, dry over Na2SO4, and filter. Concentrated the filtrate to give the title
compound as a white solid (0.070 g, 85%). MS (ES) m/e 518 (M+l).
Example 6. Preparation of 7-{l-[4-(3,3-Dimethyl-2-oxobutoxy)-3-methylphenyl]-l-
ethylpropyl} naphthalene-2-carboxylic acid

Cool a solution of 2,7-dihydroxynaphthalene (2.7 g, 31.2 mmol) and pyridine
(4.53 mL, 56.0 mmol) in CH2CL2 (100 mL) in an ice bath and treat the cooled
solution with trifluoromethanesulfonic anhydride (6.62 mL, 39.3 mmol). Remove the
cooling bath and stir the mixture at RT for 2.5 h. Quench the reaction with ice water
and dilute with CH2CL2 (200 mL). Wash the residue with water (2 x 100 mL) and
then acidify to pH 3 using IN HC1. Dry the organic layer over Na2SO4, filter and
concentrate the filtrate. Purify the product by medium pressure silica gel
34

WO 2006/069153 PCT/DS2005/046360
chromatography (10:90 EtOAc:hex to 25:75 EtOAc:hex) to give the title compound
as a yellow oil (4.1 g, 45%). MS (ES) m/e 291 (M+l).

Treat a mixture containing trifluoromethanesulfonic acid 7-(l-ethyl-l-
hydroxypropyl)naphthalen-2-yl ester (0.41 g, 14.1 rnmol), Pd(OAc)2 (0.30 g, 1.38
mmol), bis-(diphenylphosphino)ferrocene (0.705 g, 1.27 mmol), Et3N (10.2 ml., 73.2
mmol), in MeOH (12 mL) and DMSO (18 mL) with carbon monoxide at 100 psi at 80
°C for 4 h. Pour the reaction mixture into ether (300 mL) and wash with brine (5 x
100 mL). Add EtOAc (250 mL), wash the organic layer with brine, dry over
Na2SO4, and filter. Concentrate the filtrate to give the title compound as a tan solid
(2.84 g, quant). 'H NMR (400 MHz, CDC13) 5 3.98 (s, 3H), 7.23-7.29 (m, 2H), 7.78
(t, J= 8.3 Hz, 2H), 7.88-7.90 (m, 1H), 8.43 (d, J= 0.88 Hz, 1H).

Treat a solution of 7-hydroxynaphthalene-2-carboxylic acid methyl ester (2.84
g, 14.0 mmol) and benzyl bromide (1.84 mL, 15.5 mmol in DMF (14 mL) with
cesium carbonate (9.10 g, 27.9 mmol). Stir the mixture for 2 h and concentrate.
Dissolve the crude residue in EtOAc (150 mL) and 1 N HC1 (50 mL). Wash the
organic layer with brine (3 x 100 mL), dry over Na2SO4, and filter. Concentrate the
filtrate and purify using medium pressure silica gel chromatography (10:90
EtOAc:hex) to give the title compound as a white solid (1.47 g, 36%). MS (ES) We
293 (M+l).
35

WO 2006/069153 PCT/DS2005/046360

Cool a THF (30 mL) solution of 7-benzyloxynaphthalene-2-carboxylic acid
methyl ester (1.47 g, 5.03 mmol) with an ice bath and treat the cooled solution
dropwise with ethyl magnesium bromide (5.9 mL, 17.6 mmol, 3.0M in ether).
Remove the ice bath and stir the reaction for 3 h. Quench the reaction with ice water,
then treat with 1 N HC1, and concentrate to provide a crude product. Dissolve the
crude product in EtOAc (100 mL). Wash the organic layer twice with brine, dry over
Na2SO4, and filter. Concentrate the filtrate and prufiy using radial silica gel
chromatography (5:95 to 15:85 EtOAc.hex) to give a yellow solid (01.46 g, 90%). 'H
NMR (400 MHz, CDC13) §0.787 (t, J= 7.5 Hz, 6H), 1.67 (br s, 1H), 1.82-2.02 (m,
4H), 5.19 (s, 2H), 7.19-7.44 (m, 6H), 7.50 (d, J= 6.6 Hz, 2H), 7.73 (d, J= 8.8 Hz, 2H),
7.77(d,J=1.8Hz, 1H).

Treat a mixture of 3-(7-benzyloxynaphthalen-2-yl)pentan-3-ol (1.45 g, 4.53
mmol) and 5% Pd/A12CO3 (0.044 g) in EtOH (725 mL) with hydrogen at 60 psi for 8 h at
RT. Remove the catalyst by filtation and concentrate the filtrate to give the title
compound as a yellow oil (0.98 g, 94%). MS (ES) m/e 229 (M-l).
36

WO 2006/069153 PCT/DS2005/046360

Cool a CH2CL2 (30 mL) solution of 7-( 1-ethyl-ll-hydroxypropyl)naphthalen-
2-ol (0.97 g, 4.2 mmol) and pyridine (1.3 mL, 16.3 mmol) with an ice bath. Treat the
cooled solution dropwise with trifluoromethanesulfonic anhydride (1.0 mL, 6.1
mmol). Remove the cooling bath and stir the mixture for 1.5 h at RT. Quench the
reaction with ice water. Dilute the reaction mixture with EtOAc and water (100 mL
each) and acidify to pH 1 using 0.1N HC1. Dry the organic layer over Na2SO4, filter
and concentrate the filtrate. Purify by radial silica gel (2:98 to 10:90 EtOAc:hex) to
give the title compound as a colorless oil (1.46 g, 66%). MS (ES) m/e 377 (M-NH4).

Treat a mixture of trifluoromethanesulfonic acid 7-(l-ethyl-l-
hydroxypropyl)naphthalen-2-yl ester (1.0 g, 2.76 mmol), Pd(OAc)2 (0.062 g, 0.27 mmol),
6w-(diphenylphosphino)ferrocene (0.14 g, 0.25 mmol), Et3N (2.0 mL, 14.3 mmol) in
MeOH (10 mL) and DMSO (15 mL) with carbon monoxide at 100 psi at 80 °C for 4 h.
Pour the reaction mixture into ether (100 mL) and wash the resulting solution with brine
(4 x 50 mL). Add EtOAc (100 mL), wash the organic layer with brine. Dry the organic
layer over Na2SO4, filter, and concentrate the filtrate. Purify by silica gel radial
chromatography (5:95 to 15:85 EtOAc:hex) to give the title compound as a yellow oil
(0.71 g, 94%). *H NMR (400 MHz, CDC13) 5 0.792 (t, J= 7.5 Hz, 6H), 1.80-2.04 (m, 4H),
4.00 (s, 3H), 7.58 (dd, J= 8.8,1.4 Hz, 1H), 7.80-7.87 (m, 2H), 7.99 (d, J= 1.3 Hz, 1H),
8.02 (d, J= 1.8 Hz, 1H), 8.05 (d, J= 1.8 Hz, 1H), 8.61 (d, J= 1.0 Hz, 1H).
37

WO 2006/069153 PCT/DS2005/046360

Cool a CH2CL2 (20 mL) solution of 7-(l-ethyl-l-hydroxypropyl)naphthalene-
2-carboxylic acid methyl ester (0.73 g, 2.68 mmol) and o-cresol (1.54 mL, 15.0
mmol) to -78 °C; then dropwise add BF3-OEt2 (0.76 mL, 6.0 mmol). Allow the
reaction mixture to warm to RT and stir for 1 h. Quench the reaction with ice water.
Dilute the resulting mixture with EtOAc (200 mL). Wash the mixture with brine, dry
the organic layer over Na2SO4, filter and concentrate the filtrate. Purify by silica gel
radial chromatography (5:95 to 35:65 EtOAc:hex) to give the title compound as a
yellow oil (0.93 g, 86%). MS (ES) m/e 363 (M+l).

Stirr a mixture of 7-[l-ethyl-l-(4-hydroxy-3-
methylphenyl)propyl]naphthalene-2-carboxylic acid methyl ester (0.87 g. 2.40 mmol),
1-bromopinacolone (1.54 g, 8.68 mmol), and potassium carbonate (2.4 g, 17.4 mmol)
in acetone (20 mL) for 4 h at RT. Concentrate the reaction mixture and then dilute the
residue with EtOAc (100 mL) and water (50 mL). Adjust the pH of the mixture to 1
using 1 N HC1. Discard the aqueous layer. Wash the organic layer with brine, dry
over Na2SO4 and filter. Concentrate the filtrate and purified by silica gel radial
chromatography (5:95 EtOAc:hex to 15:85 EtoAc:hex) to give the title compound as a
white solid (1.1 g, 82%). MS (ES) m/e 461 (M+l).
38

WO 2006/069153 PCT/DS2005/046360

Treat 7-{ l-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-l-
ethylpropyl}naphthalene-2-carboxylic acid methyl ester (1.1 g, 2.4 mmol) in THF (15
mL) and MeOH (30 mL) with 2N NaOH (6.0 mL, 12.0 mmol) and heat to 55 °C for 16 h.
Then concentrate the reaction mixture and dilute the residue with CH2CL2 and water (50
mL each). Acidify the mixture to pH 1 using IN HC1. Discard the aqueous layer and
wash the organic layer with brine. Dry the organic layer over Na2SO4, filter and
concentrate the filtrate. Purify by silica gel radial chromatography (2:98 MeOH:CH2CL2
to 10:90 MeOH:CH2CL2) to give the title compound as a yellow solid (0.96 g, 90%). MS
(ES) m/e 447 (M+l).
Example 7. Diastereomeric isomer pair 1 of 2-[6-{ l-ethyl-l-[4-(l-ethyl-2-hydroxy-
3,3-dimethyl-butoxy)-3-methyl-phenyl]-propyl}-naphthalene-2-carbonylamino|acetic
acid

Slowly add bromine (10.87 ml, 212.15 mmol) to 2, 2-dimethylhexane-3-one
(27.20 g, 212.15 mmol) in ether (200 ml) and allow the reaction to stir for 14 h.
Combine the reaction mixture with water (200 ml) and partition. Dry the organic
layer over Na2SO4, filter nd then concentrate the filtrate to provide the title
compound as a yellow oil (48.2 g, quant^NMR (400MHz, CDC13) 5 ppm: 1.01 (t, J
39

WO 2006/069153 PCT/DS2005/046360
= 7.6 Hz, 3H), 1.27 (s, 9H), 2.03 (m, 2H), 4.58 (t, J = 7.2 Hz, 1H). High Res. ES-MS:
207.0348; calc. for C8H15BrO+H: 207.0384.

40
Add 4-bromo-2,2-dimethylhexane-3-one (660 mg, 3.187 mmol) to a mixture
of 6-[l-ethyl-l-(4-hydroxy-3-metliylphenyl)propyl]naphthalene-2-carboxylicacid
methyl ester (1.1 g, 3.035 ramol), and K2CO3 (629 mg, 4.55 mmol) in DMF (10 ml).
Maintain the reaction mixture 45° C for 14 h. Add an additional amount of 4-bromo-
2,2-dimethylhexane-3-one (314 mg, 1.52 mmol) and maintain the mixture at 60° C
while stirring for 62 h. Cool the reaction mixture and dilute it with CH2C12, filter,
and concentrate in vacuo. Chromatograph the resulting residue (CH2C12 to 1%
EtOAc/CH2C12) to give the title compound as a colorless viscous oil (1.299 g, 88%).
1NMR (400MHZ, CDC13) δ ppm: 0.62 (t, J = 7.2 Hz, 6H), 1.01 (t, J = 7.6 Hz, 3H),
1.16 (s, 9H), 1.88 (m, 2H), 2.16 (m, 4H), 2.19 (s, 3H), 3.97 (s, 3H), 4.86 (dd, J = 5.2,
1.6 Hz, 1H), 6.53 (d, J = 8.4 Hz, 1H), 6.88 (m, 2H), 7.14 (dd, J = 7.2, 1.6 Hz, 1H),
7.73 (d, J = 8.8 Hz, 1H), 7.82 (s, 1H), 7.85 (d, J = 8.8 Hz, 1H), 8.04 (dd, J = 6.4, 2.0
Hz, 1H), 8.52 (s, 1H). High Res. ES-MS: 511.2824; calc. for C32H40O4+Na:
511.2825


WO 2006/069153 PCT/DS2005/046360
Following the procedure described in Example 2; treat 6-{ l-[4-(3,3-dimethyl-
l-ethyl-2-oxobutoxy)-3-methylphenyl]-l-ethylpropyl}naphthalene-2-carboxylicacid
methyl ester with NaBH4 in THF at 0 C. Chromatograph the residue (CH2C12 to 2%
EtOAc/CH2C12) to give diastereomeric isdmer pair 1 of the title compound as a
glassy foam (1.004 g, 77%) and diastereomeric isomer pair 2 of the title compound as
a glassy foam (102 mg, 8%).
Diastereomeric isomer pair 1: 1NMR (400MHz, CDC13) δ ppm: 0.64 (t, J = 7.6 Hz,
6H), 0.93 (t, J = 8.0 Hz, 3H), 0.93 (s, 9H), 1.70 (m, 1H), 1.81 (m, 1H), 2.12 (s, 3H),
2.17 (m, 4H), 2.61 (bs, 1H), 3.27 (s, 1H), 3.97 (s, 3H), 4.27 (dd, J = 5.6, 3.6 Hz, 1H),
6.63 (d, J = 8.8 Hz, 1H), 6.90 (s, 1H), 6.93 (d, J = 8.4 Hz, 1H), 7.18 (d, J = 8.8 Hz,
1H), 7.75 (d, J = 8.8 Hz, 1H), 7.83 (s, 1H), 7.86 (d, J = 8.4 Hz, 1H), 8.04 (dd, J = 7.2,
1.2 Hz, 1H), 8.52 (s, 1H). High Res. ES-MS: 513.2914; calc. for C32H42O4+Na:
513.2981
Analysis for C32H42O4; Calcd: C, 78.33; H, 8.63; N, 0.00, Found: C, 78.21; H, 8.75; N,
0.11.
Diastereomeric isomer pair 2:
41
1NMR (400MHZ, CDC13) δ ppm: 0.64 (t, J = 7.2 Hz, 6H), 0.99 (t, J = 4.4 Hz, 3H),
0.99 (s, 9H), 1.81 (m, 2H), 2.12 (s, 3H), 2.16 (m, 4H), 3.59 (d, J = 4.0 Hz, 1H), 3.97
(s, 3H), 4.35 (m, 1H), 6.67 (d, J = 8.4 Hz, 1H), 6.91 (m, 2H), 7.18 (dd, J = 6.8, 2.0 Hz,
1H), 7.75 (d, J = 8.8 Hz, 1H), 7.83 (s, 1H), 7.86 (d, J = 8.8 Hz, 1H), 8.05 (dd, J = 6.8,
2.2 Hz, 1H), 8.52 (s, 1H). High Res. ES-MS: 513.2973; calc. for C32H42O4+Na:
513.2981


WO 2006/069153 PCT/DS2005/046360
propyl}-naphthalene-2-carboxylic acid methyl ester (702 mg, 1.431 mmol), THF (9
ml), MeOH (3 ml), and ICO (1 ml). Heat the reaction mixture to 60 °C and stir it for
14 h. Cool and partition the reaction mixture between Et2O and IN HC1. Dry the
organic layer over MgSO4, filter, and concentrate the filter in vacuo to give the title
compound as a glassy solid (665 mg, 97%). 1NMR (400MHZ, CDC13) δ ppm: 0.64 (t,
J = 7.6 Hz, 6H), 0.93 (t, J = 8.4 Hz, 3H), 0.93 (s, 9H), 1.72 (m, 1H), 1.82 (m, 1H),
2.12 (s, 3H), 2.19 (q, 4H), 3.28 (s, 1H), 4.28 (dd, J = 6.0, 3.2 Hz, 1H), 6.65 (d, J = 8.4
Hz, 1H), 6.90 (d, J = 2.0 Hz, 1H), 6.94 (dd, J = 6.0, 2.4 Hz, 1H), 7.21 (dd, J = 7.2,1.6
Hz, 1H), 7.78 (d, J = 8.8 Hz, 1H), 7.86 (s, 1H), 7.89 (d, J = 8.8 Hz, 1H), 8.09 (dd, J =
6.8,1.6 Hz, 1H), 8.62 (s, 1H). High Res. ES-MS: 499.2832; calc. for C31H40O4+Na:
499.2825
Analysis for C31H40O4; Calcd: C, 78.11; H, 8.46; N, 0.00, Found: C, 78.03; H, 8.59; N,
0.12.
E. Diastereomeric isomer pair 1 of 6-{l-ethyl-l-[4-(l-ethyl-2-hydroxy-3,3-dimethyl-
butoxy)-3-methyl-phenyl]-propyl}-naphthalene-2-carbonylaminoacetic acid methyl
ester

Add glycine methyl ester hydrochloride (95 mg, 0.755 mmol), HOBT (102
mg, 0.755 mmol), EDCI (206 mg, 1.08 mmol), and Et3N (0.4 ml, 0.726 mmol) to
diastereomeric isomer pair 1 of 6-{l-ethyl-l-[4-(l-ethyl-2-hydroxy-3,3-dimethyl-
butoxy)-3-methyI-phenyl]-propyl}-naphthalene-2-carboxylic acid (343 mg, 0.72
mmol) and CH2C12 (5 ml). Stir the reaction for 14 h. Concentrate the reaction
mixture in vacuo, and chromatograph the residue (CH2C12 to 15% EtOAc/CH2C12)
to give the title compound as a colorless foam (373 mg, 95%). 1NMR (400MHZ,
CDC13) δ ppm: 0.64 (t, J = 7.6 Hz, 6H), 0.93 (t, J = 8.4 Hz, 3H), 0.93 (s, 9H), 1.68 (m,
1H), 1.81 (m, 1H), 2.12 (s, 3H), 2.18 (q, 4H), 2.60 (bs, 1H), 3.27 (s, 1H), 3.83 (s, 3H),
42

WO 2006/069153 PCT/DS2005/046360
4.27 (dd, J = 5.6, 3.2 Hz, 1H), 4.31 (d, J = 5.2 Hz, 2H), 6.63 (d, J = 8.0 Hz, 1H), 6.75
(t, J = 4.8 Hz, 1H), 6.89 (d, J = 2.4 Hz, 1H), 6.93 (dd, J = 6.4,2.0 Hz, 1H), 7.18 (dd, J
= 6.8, 2.0 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.83 (d, J = 2.0, 1H), 7.86 (m, 2H), 8.26
(s, 1H). High Res. ES-MS: 570.3116; calc. for C34H45NO5+Na: 570.3196.
Analysis for C34H45NO5; Calcd: C, 74.56; H, 8.28; N, 2.56, Found: C, 74.28; H,
8.23; N, 2.68.

Add 2.5 M LiOH/H2O (0.82 ml, 2.04 mmol) to diastereomeric isomer pair 1
of 2-[6-{l-ethyl-l-[4-(l-ethyl-2-hydroxy-3,3-dimethyl-butoxy)-3-methyl-phenyl]-
propyl}-naphthalene-2-carbonylamino]acetic acid methyl ester (373 mg, 0.681 mmol)
in THF (3 ml), and MeOH (1.5 ml). Stir the reaction for 14 h; then partition the
reaction mixture between Et20 and IN HC1. Dry the organic layer with MgSO4,
concentrate and triturate the residue with CH2C12/MeOH/hexanes to give the title
compound as a white solid (310 mg, 85%). 1NMR (400MHZ, CDC13) δ ppm: 0.64 (t,
J = 7.2 Hz, 6H), 0.93 (t, J = 8.0 Hz, 3H), 0.93 (s, 9H), 1.68 (m, 1H), 1.81 (m, 1H),
2.11 (s, 3H), 2.15 (q, 4H), 3.28 (s, 1H), 4.27 (dd, J = 5.2, 3.6 Hz, 1H), 4.35 (d, J = 4.8
Hz, 2H), 6.63 (d, J = 8.0 Hz, 1H), 6.83 (t, J = 4.8 Hz, 1H), 6.89 (s, 1H), 6.93 (dd, J =
6.4, 2.2 Hz, 1H), 7.18 (dd, J = 7.2,1.6 Hz, 1H), 7.74 (d, J = 8.8 Hz, 1H), 7.88 (m,
3H), 8.27 (s, 1H). High Res. ES-MS: 556.3046; calc. for C33H43NO5+Na: 556.3040.
Example 8. Preparation of diastereomeric isomer pair 1 of N-memyl-2-[6-{ 1-ethyl-l-
[4-( l-ethyl-2-hydroxy-3,3-dimethyl-butoxy)-3-methyl-phenyl]-propyl} -naphthalene-
2-carbonyl-amino]acetic acid
43

WO 2006/069153 PCT/DS2005/046360

44
Following a procedure analogous to Example 7E esterify the diastereomeric
isomerpair 1 of 6-{l-emyl4-[4-(l-emyl-2-hydroxy-3,3-dimethyl-butoxy)-3-methyl-
phenyl]-propyl}-naphthalene-2-carboxylic acid using N-methyl glycine ethyl ester
hydrochloride to provide the title compound as a white foam (315 mg, 88%). 1NMR
(400MHz, CDC13) 5 ppm: 0.64 (t, J = 7.2 Hz, 6H), 0.93 (t, J = 8.4 Hz, 3H), 0.93 (s,
9H), 1.31 (m, 3H), 1.68 (m, 1H), 1.80 (m, 1H), 2.12 (s, 3H), 2.17 (q, 4H), 2.60 (bs,
1H), 3.11 (s, 2H), 3.16 (s, 1H), 3.27 (s, 1H), 4.05 (s, 0.73H), 4.27 (m, 3H), 4.32 (s,
1.27H), 6.63 (d, J = 8.8 Hz, 1H), 6.90 (s, 1H), 6.93 (d, J = 8.8 Hz, 1H), 7.16 (d, J =
10.0 Hz, 1H), 7.49 (m, 1H), 7.55 (d, J = 7.6 Hz, 1H), 7.68 (m, 1H), 7.81 (s, 1H), 7.87
(m, 2H). High Res. ES-MS: 598.3488; calc. for C36H49NO5+Na: 598.3509. Analysis
for C36H49NO5; Calcd: C, 75.10; H, 8.58; N, 2.43, Found: C, 75.04; H, 8.58; N,
2.43.


WO 2006/069153 PCT/DS2005/046360
Following a procedure analogous to Example 7F, esterify the diastereorneric
isomer pair 1 of N-methyl-2-[6-{ l-ethyl-l-[4-(l-ethyl-2-hydroxy-3,3-dimethyl-
butoxy)-3-methyl-phenyl]-propyl}-naphthalene-2-carbonyl-amino]acetic acid ethyl
ester in THF and EtOH to give the title compound as a white solid (300 mg, quant.).
1NMR (400MHZ, CDC13) 5 ppm: 0.64 (t, J = 7.2 Hz, 6H), 0.93 (t, J = 7.6 Hz, 3H),
0.93 (s, 9H), 1.65 (m, 1H), 1.83 (m, 1H), 2.12 (s, 3H), 2.15 (q, 4H), 3.16 (s, 3H), 3.28
(s, 1H), 4.12 (bs, 0.5H), 4.26 (dd, J = 5.2,3.6 Hz, 1H), 4.36 (s, 1.25H), 6.63 (d, J =
8.4 Hz, 1H), 6.90 (s, 1H), 6.93 (d, J = 8.8 Hz, 1H), 7.17 (d, J = 8.0 Hz, 1H), 7.53 (m,
1H), 7.68 (m, 1H), 7.82 (s, 1H), 7.87 (m, 1H), 7.93(m, 1H). High Res. ES-MS:
570.3140; calc. for C34H45NO5+Na: 570.3196.

Treat 3'-[4-(2-Hydroxy-3,3-dimethyl-butoxy)-3-methyl-phenyl]-3' [(12-
carboxylic acid) -naphthalene] pentane (1 eq.) in CH2CL2 with, Et3N (1.1 eq.)
(PhO)2PO(N3) (1.1 eq) and allow the reaction to stir for about 1 h Then concentrate
the reaction mixture, and add the concentrated solution to a 90°C solution of t-BuOH
and heat with an open stream of nitrogen for about 1.75 h. Cool the reaction to RT,
dissolve in a minimal of 1:1 CH2Cl2:10% EtOAc/Hex, and chromatographed (10%
EtOAc/Hex) to give the title compound.
Example 10. 3'-f4-(2-Hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]-3'-[12-amino-
napthaline]pentane.
45

WO 2006/069153 PCT/DS2005/046360

Treat mixture of 3'-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]-3I-[12-
(t-butoxycarbonylamino)-napthaline]pentane (1 eq.), anisole (about 20 eq.) in CH2CI2 (5
ml) with TFA (excess). Stir the reaction for about 2 h, concentrate, and partition the
reaction mixture between EtOAc/satd Na2CO3. Wash the organic layer with water, dry
over Na2SO4, and filter. Concentrate the filtrate and chromatograph the residue (50%
CHCl3/Hex to CHCI3) to give the title compound.
Compounds of the Invention - Salts, Stereoisomers, & Prodrugs:
Salts of the compounds represented by Formula I are an additional aspect of the
invention. The skilled artisan will also appreciate that the family of compounds of
Formula I include acidic and basic members and that the present invention includes
pharmaceutically acceptable salts thereof.
In those instances where the compounds of the invention possess acidic or basic
functional groups various salts may be formed which are more water soluble and
physiologically suitable than the parent compound. Representative pharmaceutically
acceptable salts, include but are not limited to, the alkali and alkaline earth salts such as
lithium, sodium, potassium, ammonium, calcium, magnesium, aluminum, zinc, and the
like. Sodium and potassium salts are particularly preferred. Salts are conveniently
prepared from the free acid by treating the acid in solution with a base or by exposing the
acid to an ion exchange resin. For example, a carboxylic acid substituent on the
compound of Formula I may be selected as -CO2H and salts may be formed by reaction
with appropriate bases (e.g., NaOH, KOH) to yield the corresponding sodium and
potassium salt.
Included within the definition of pharmaceutically acceptable salts are the
relatively non-toxic, inorganic and organic base addition salts of compounds of the
present invention, for example, ammonium, quaternary ammonium, and amine cations,
46

WO 2006/069153 PCT/DS2005/046360
derived from nitrogenous bases of sufficient basicity to form salts with the compounds of
this invention (see, for example, S. M. Berge, et al., "Pharmaceutical Salts," J. Phar. Sci.,
66: 1-19 (1977)). Moreover, the basic group(s) of the compound of the invention may be
reacted with suitable organic or inorganic acids to form salts such as acetate,
benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, camsylate,
carbonate, chloride, choline, clavulanate, citrate, chloride, chloroprocaine, choline,
diethanolamine, dihydrochloride, diphosphate, edetate, edisylate, estolate, esylate,
ethylenediamine, fluoride, fumarate, gluceptate, gluconate, glutamate, glycolyteirsanilate,
hexylresorcinate, hydrabamine, bromide, chloride, hydrobromide, hydrochloride,
hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate,
malseate, mandelate, meglumine, mesylate, mesviate, methylbromide, methylnitrate,
methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, palmitate, pamoate,
pantothenate, phosphate, polygalacturonate, procane, salicylate, stearate, subacetate,
succinate, sulfate, tannate, tartrate, teoclate, tosylate, trifluoroacetate, trifluoromethane
sulfonate, and valerate.
Certain compounds of the invention may possess one or more chiral centers and
may thus exist in optically active forms. Likewise, when the compounds contain an
alkenyl or alkenylene group there exists the possibility of cis- and trans- isomeric forms
of the compounds. The R- and S- isomers and mixtures thereof, including racemic
mixtures as well as mixtures of cis- and trans- isomers, are contemplated by this
invention. Additional asymmetric carbon atoms can be present in a substituent group
such as an alkyl group. All such isomers as well as the mixtures thereof are intended to
be included in the invention. If a particular stereoisomer is desired, it can be prepared by
methods well known in the art by using stereospecific reactions with starting materials
which contain the asymmetric centers and are already resolved or, alternatively by
methods which lead to mixtures of the stereoisomers and subsequent resolution by known
methods. For example, a chiral column may be used such as those sold by Daicel
Chemical Industries identified by the trademarks:
CHIRALPAK AD, CHIRALPAK AS, CHIRALPAK OD, CHIRALPAK OJ,
CHIRALPAK OA, CHIRALPAK OB, CHIRALPAK OC, CHIRALPAK OF,
CHIRALPAK OG, CHIRALPAK OK, and CHIRALPAK CA-1.
47

WO 2006/069153 PCT/DS2005/046360
By another conventional method, a racemic mixture may be reacted with a single
enantiomer of some other compound. This changes the racemic form into a mixture of
diastereomers. These diastereomers, because they have different melting points, different
boiling points, and different solubilities can be separated by conventional means, such as
crystallization.
Prodrugs are derivatives of the compounds of the invention which have
chemically or metabolically cleavable groups and become by solvolysis or under
physiological conditions the compounds of the invention which are pharmaceutically
active in vivo. Derivatives of the compounds of this invention have activity in both their
acid and base derivative forms, but the acid derivative form often offers advantages of
solubility, tissue compatibility, or delayed release in a mammalian organism (set:,
Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs
include acid derivatives well known to practitioners of the art, such as, for example, esters
prepared by reaction of the parent acidic compound with a suitable alcohol, or amides
prepared by reaction of the parent acid compound with a suitable amine. Simple aliphatic
or aromatic esters derived from acidic groups pendent on the compounds of this invention
are preferred prodrugs. In some cases it is desirable to prepare double ester type prodrugs
such as (acyloxy) alkyl esters or ((alkoxycarbonyl)oxy)alkyl esters. Particularly preferred
esters to use as prodrugs are; methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl,
morpholinoethyl, and N,N-diethylglycolamido.
N,N-diethylglycolamido ester prodrugs may be prepared by reaction of the
sodium salt of a compound of Formula I (in a medium such as dimethylformamide) with
2-chloro-N,N-diethylacetamide (available from Aldrich Chemical Co., Milwaukee,
Wisconsin USA; Item No.25,099-6).
Morpholinylethyl ester prodrugs may be prepared by reaction of the sodium salt of
a compound of Formula I (in a medium such as dimethylformamide) 4-(2-
chloroethyl)morpholine hydrochloride (available from Aldrich Chemical Co., Milwaukee,
Wisconsin USA, Item No. C5,220-3). For example, prodrugs may be prepared by
reaction of the sodium salt for a compound of Formula I with;
48

WO 2006/069153 PCT/DS2005/046360

Also, lower alkyl (viz., C1-C8) ester prodrugs may be prepared by conventional
means such as reacting the sodium or potassium salt (derived by forming the salt of any
acidic compound of the invention; viz., reaction of a base such as KOH with an acidic
group such as -CO2H) of a compound of Formulae I with an alkyl iodide such as methyl
iodide, ethyl iodide, n-propyl iodide, isopropyl iodide.
Pharmaceutical Formulations containing the Novel Compounds of the Invention:
Pharmaceutical formulations of the invention are prepared by combining (e.g.,
mixing) a therapeutically effective amount of the compound of the invention
(compounds of Formula I) together with a pharmaceutically acceptable carrier or
diluent. The present pharmaceutical formulations are prepared by known procedures
using well-known and readily available ingredients.
In making the compositions of the present invention, the compounds of the
invention will usually be admixed with a carrier, or diluted by a carrier, or enclosed
within a carrier which may be in the form of a capsule, sachet, paper or other
container. When the carrier serves as a diluent, it may be a solid, semi-solid or liquid
material which acts as a vehicle, or can be in the form of tablets, pills, powders;,
lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a
liquid medium), or ointment, containing, for example, up to 10% by weight of the
compound. The compounds of the present invention are preferably formulated prior to
administration.
49

WO 2006/069153 PCT/DS2005/046360
The compounds of the invention may also be delivered by suitable
formulations contained in a transderm patch. Alternatively, the compounds of the
invention may be delived to a patient by sublingual administration.
For the pharmaceutical formulations any suitable carrier known in the art can be
used. In such a formulation, the carrier may be a solid, liquid, or mixture of a solid and a
liquid. Solid form formulations include powders, tablets and capsules. A solid carrier
can be one or more substances which may also act as flavoring agents, lubricants,
solubilisers, suspending agents, binders, tablet disintegrating agents and encapsulating
material.
Tablets for oral administration may contain suitable excipients such as calcium
carbonate, sodium carbonate, lactose, calcium phosphate, together with disintegrating
agents, such as maize, starch, or alginic acid, and/or binding agents, for example,
gelatin or acacia, and lubricating agents such as magnesium stearate, stearic acid, or
talc.
In powders the carrier is a finely divided solid which is in admixture with the
finely divided Active Ingredient. In tablets a compound of the invention is mixed with a
carrier having the necessary binding properties in suitable proportions and compacted in
the shape and size desired. The powders and tablets preferably contain from about 1 to
about 99 weight percent of the compound of this invention. Suitable solid carriers are
magnesium carbonate, magnesium stearate, talc, sugar lactose, pectin, dextrin, starch,
gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, low melting
waxes, and cocoa butter.
Sterile liquid form formulations include suspensions, emulsions, syrups and
elixirs.
The Active Ingredient may be dissolved or suspended in a pharmaceutically
acceptable carrier, such as sterile water, sterile organic solvent or a mixture of both. The
compounds can often be dissolved in a suitable organic solvent, for instance aqueous
propylene glycol. Other compositions can be made by dispersing the finely divided
compounds of the invention in aqueous starch or sodium carboxymethyl cellulose
solution or in a suitable oil.
Methods of Using the Compounds of the Invention:
50

WO 2006/069153 PCT/DS2005/046360
Many disease states are benefited by treatment with the compounds of Formula I
include, but are not limited to: disease states characterized by abnormal calcium
regulation, abnormal cell proliferation, abnormal cell differentiation, abnormal immune
response, abnormal dermatological conditions, neurodegenerative condition,
inflammation, vitamin D sensitivity, and/or hyperproliferative disorders.
Specific disease states benefited by treatment with one or more of the compounds
of Formula I include, but are not limited to: Acne, Actinic keratosis. Alopecia,
Alzheimer's disease, Benign prostatic hyperplasia, Bladder cancer, Bone maintenance in
zero gravity, Bone fracture healing, Breast cancer, Chemoprovention of Cancer, Crohn's
disease, Colon cancer, Type I diabetes, Host-graft rejection, Hypercalcemia, Type II
diabetes, Leukemia, Multiple sclerosis, Myelodysplastic syndrome, Insufficient sebum
secretion, Osteomalacia, Osteoporosis, Insufficient dermal firmness, Periodontal disease,
Insufficient dermal hydration, Psoriatic arthritis, Prostate cancer. Psoriasis, Renal
osteodystrophy, Rheumatoid arthritis, Scleroderma. Skin cancer, Systemic lupus ,
rythematosus, Skin cell damage from mustard vesicants, Ulcerative colitis, Vitiligo, and
Wrinkles.
Particularly preferred is the treatment of psoriasis and/or osteoporosis by
administration to a mammal (including a human) of a therapeutically effective amount of
compounds of Formula I. By "pharmaceutically effective amount" it is meant that
quantity of pharmaceutical agent corresponding to formulae I which prevents, removes
or reduces the deleterious effects of a disease state in mammals, including humans.
The specific dose of a compound administered according to this invention to
obtain therapeutic or prophylactic effects will, of course, be determined by the particular .
circumstances surrounding the case, including, for example, the compound administered, .
the route of administration and the condition being treated. Typical daily doses will
contain a pharmaceutically effective amount typically in the range of from about 0.0001
mg/kg/day to about 50 mg/kg/day of body weight of an active compound of this
invention. Preferably the dose of compounds of the invention will be from 0.0001 to 5
mg/kg/day of body weight.
Preferably compounds of the invention or pharmaceutical formulations
containing these compounds are in unit dosage form for administration to a mammal.
The unit dosage form can be a capsule or tablet itself, or the appropriate number of any
51

WO 2006/069153 PCT/DS2005/046360
of these. The quantity of Active Ingredient in a unit dose of composition may be varied
or adjusted from about 0.0001 to about 1000 milligrams or more according to the
particular treatment involved. It may be appreciated that it is necessary to make
routine variations to the dosage depending on the age and condition of the patient.
Dosage will also depend on the route of administration. The compounds of the
invention may be administered by a variety of routes including oral, aerosol, rectal,
transdermal, sublingual, subcutaneous, intravenous, intramuscular, and intranasal.
Particularly preferred is the treatment of psoriasis with an ointment type formulation
containing the compounds of the invention. The ointment formulation may be applied
as needed, typically from one to 6 times daily.
Treatment of psoriasis is preferably done with topical application by a
formulation in the form of a cream, oil, emulsion, paste or ointment containing a
therapeutically effective amount of a compound of the invention. The formulation for
topical treatment contains from 0.5 to 0.00005 weight percent, preferably from .05 to
0.0005 weight percent, and most preferably from 0.025 to 0.001 of a Active Ingredient.
For example, two semisolid topical preparations useful as vehicles for VDR
modulators in treatment and prevention of psoriasis are as follows:
Polyethylene Glycol Ointment USP (p. 2495)
Prepare Polyethylene Glycol Ointment as follows:
Polyethylene Glycol 3350 400 g.
Polyethylene Glycol 400 600 g.
To make 1000 g.
Heat the two ingredients on a water bath to 65°C. Allow to cool, and stir until
congealed. If a firmer preparation is desired, replace up to 100 g of the polyethylene
glycol 400 with an equal amount of polyethylene glycol 3350.
Hydrophilic Ointment USP (p. 1216)
Prepare Hydrophilic Ointment as follows:
Methylparaben 0.25 g.
Propylparaben 0.15 g.
Sodium Lauryl Sulfate 10 g.
Propylene Glycol 120 g.
Stearyl Alcohol 250 g.
52

WO 2006/069153 PCT/DS2005/046360
White Petrolatum 250 g.
Purified Water 370 g.
To make about 1000 g.
The Stearyl Alcohol and White Petrolatum are melted on a steam bath, and
warmed to about 75°C. The other ingredients, previously dissolved in the water are
added, wanned to 75°C, and the mixture stirred until it congeals.
For each of the above formulations the Active Ingredient is added during the
heating step in an amount that is from 0.5 to 0.00005 weight percent, preferably from .05
to 0.0005 weight percent, and "USP" most preferably from 0.025 to 0.001 weight percent
of the total ointment weight. (Source: - United States Pharmacopoeia 24, United States
Pharmacopeial Convention, 1999)
Conventional therapy for osteoporosis includes; (i) estrogens, (ii) androgens, (iii)
calcium supplements, (iv) vitamin D metabolites, (v) thiazide diuretics, (vi) calcitonin,
(vii) bisphosphonates, (viii) SERMS, (ix) fluorides and (x) Parathyroid hormone (PTH)
(see, Harrison's Principles of Internal Medicine, 13th edition, 1994, published by McGraw
Hill Publ., ISBN 0-07-032370-4, pgs. 2172-77; the disclosure of which is incorporated
herein by reference). Any one or a combination of these conventional therapies may be
used in combination with the method of treatment using compounds of Formula I as
taught herein. For example, in a method of treating osteoporosis, the vitamin D receptor
modulator compounds of the invention may be administered separately or simultaneously
with a conventional therapy. Alternatively, the vitamin D receptor modulator compounds
of the invention may be combined with conventional therapeutic agents in a formulation
for treatment of osteoporosis such as set out below:
A formulation for treating osteoporosis comprising:
Ingredient (Al): a vitamin D receptor modulator represented by Formula
(I), or a pharmaceutically acceptable salt or prodrug derivative
thereof;
Ingredient (Bl): one or more co-agents that are conventional for treatment
osteoporosis selected from the group consisting of: estrogens,
androgens, calcium supplements, vitamin D metabolites, thiazide
diuretics, calcitonin, bisphosphonates, SERMS, fluorides, and PTH
Ingredient (Cl): optionally, a carrier or diluent.
53

WO 2006/069153 PCT/DS2005/046360
Typically useful formulations are those wherein the weight ratio of (Al) to (Bl) is from
10:1 to 1:1000 and preferably from 1:1 to 1:100.
Combination Therapy for Psoriasis:
Conventional therapy for psoriasis includes topical glucocorticoids, salicylic acid,
crude coal tar, ultraviolet light, and methotrexate (see, Harrison's Principles of Internal
Medicine, 13th edition, 1994, published by McGraw Hill Publ., ISBN 0-07-032370-4, pgs.
2172-77). Any one or combination of these conventional therapies may be used in
combination with the method of treatment using compounds of Formula I as taught
herein. For example, in a method of treating psoriasis, the vitamin D receptor modulator
compounds of the invention (e.g., as defined by Formula I) may be topically administered
separately or simultaneously with a conventional therapy. Alternatively, the vitamin D
receptor modulator compounds of the invention may be combined with conventional
therapeutic agents in a topically applied formulation for treatment of psoriasis such as set
out below:
A formulation for treating psoriasis comprising:
Ingredient (A2): a vitamin D receptor modulator represented by
Formula(I), or a pharmaceutically acceptable salt or prodrug
derivative thereof;
Ingredient (B2): one or more co-agents that are conventional for treatment
psoriasis selected from the group consisting of: topical
glucocorticoids, salicylic acid, or crude coal tar.
Ingredient (C2): optionally, a carrier or diluent.
Typically useful formulations are those wherein the weight ratio of (A2) to (B2) is from
1:10 to 1:100000 and preferably from 1:100 to 1:10000.
54

55
WO 2006/069153 PCT/DS2005/046360


WO 2006/069153 PCT/DS2005/046360

Explanation of Tables 2 and 3 column numerical superscripts:
1. Test Compound numbers refer to the products of the corresponding Example
Nos. that is, compounds within the scope of the invention.
2. The RXR-VDR heterodimerization (SaOS-2 cells) test is described in the
"Assay" section of the Description, infra.
3. The VDR CTF (Caco-2 cells) test is described in the "Assay" section of the
Description, infra.
4. The OCN Promoter test is described in the "Assay" section of the Description,
infra.
5. The Mouse Hypercalcemia test is described in the "Assay" section of the
Description, infra.
6. The keratinocyte proliferation assay is described in the "Assay" section of
the Description, infra.
7. The IL-10 induction assay is described in the "Assay" section of the
Description, infra.
Assay Methods
Use of the Assay Methods:
The evaluation of the novel compounds of the invention for osteoporosis and other
related diseases is done using a plurality of test results. The use of multiple assays is
beneficial since it is preferred that the combined properties of (i) high activity for the
vitamin D receptor, and (ii) prevention of hypercalcemia be achieved to effect treating
diseases, which are also aspects of this invention. Some of the tests described below are
believed related to other tests and measure related properties of compounds.
Consequently, a compound may be considered to have utility in the practice of the
invention if it meets at least one preferably two or more, if not all, of the acceptance
criteria for the above described tests.
56

WO 2006/069153 PCT/DS2005/046360
The evaluation of the novel compounds of the invention for psoriasis is done
using the Keratinocyte Proliferation Assay in combination with other assays that measure
inhibition of IL-2 production and stimulation of IL-10 production in peripheral blood
mononuclear cells (PBMCs).
Brief Description, Utility and Acceptance Criteria for the Assay Methods:
1. The RXR-VDR heterodimerAssay.
This assay provides the VDR activity of a test compound. It is desirable to have
low EC50 values for a compound in this assay. The lower the EC50 value, the more
active the compound will be as a VDR agonist. Desired assay results are EC50 values
less than or equal to 600 nM. Preferred assay results are less than 250 nM, and most
preferably less than 150 nM.
(1) Materials and Method for RXR-VDR Heterodimerization Assay Transfection
Method: Reagents: FuGENE 6 Transfection Reagent (Roche Cat # 1 814 443);
Growth Media: D-MEM High Glucose (Gibco BRL Cat # 11054-020), 10% heat
inactivated FBS, (Gibco BRL Cat# 10092-147) 1% antibiotic-antimycotic (Ab-Am);
(Gibco BRL Cat # 15240-062 ).
Cells: Grow SaOS-2 cells in T-150 cm2 culture flasks in growth media keeping the
density at 5-6 x 105 cells/ml. Passage cells 1:3 twice a week. Add Trypsin EDTA (Gibco
BRL Cat # 25300-020) and incubate. Resuspend cells in plating media and transfer into
growth media.
Wash Media: HBSS Low Glucose Without Phenol Red (Gibco BRL Cat # 14175-095),
1% Ab-Am. Plating Media: D-MEM Low Glucose Without Phenol Red (Gibco BRL Cat
# 11054-020), 1% Ab-Am; D-MEM; 10 % Stripped FBS (Hyclone Cat# SH3OO68.O3
Lot#AHM9371);
Transfection / Treatment Media: D-MEM Low Glucose Without Phenol Red only; T-150
cm2 culture flask: Use Corning Coastar T-150 cm2 culture flask (Cat # 430825) to grow
the cells.
57

WO 2006/069153 PCT/DS2005/046360
Luciferase Assay Reagent: Use Steady-Glo Luciferase Reagent from Promega (Cat #
E2550) Consists of: E2533 Assay Substrate, lyopholized product and E2543 Ass;ay
Buffer. Thaw at room temperature and store.
Cell Harvesting/Count: Aspirate media from culture flask, rinse cells with HBSS and
aspirate. Add trypsin and incubate. When cells appear detached, resuspend cells in
growth media. Transfer into a new flask with fresh growth media for passaging the cells.
Plate 96 well plates and two extra plates. Mix the cell suspension using pipette. To count
the cells using a Hematocytometer.
Plate seeding: Use plating media 10 % Stripped FBS in D-MEM Low Glucose, without
Phenol Red, 1% Ab-Am. Plate 14 plates @ 165μl / well. In sterile flask add cell
suspension to plating media and mix. Add cells / well. Place the cells in the incubator.
Cells should be about 75 % confluent prior to transfection. DAY 2: Transfection: Step 1,
DNA and Media: Add plain DMEM media to tubes for mixing the DNA; add the
Reporter gene pFR-LUC; and add the Gal4-RXR-DEF and VP16-VDR-LBD. Step 2,
FuGENE and Media: Prepare plain DMEM media in a tubes for mixing FuGENE, add
FuGENE 6 Transfection Reagent, and mcubate. Step 3, FuGENE, DNA and Media
Complex: Add FuGENE Media complex from step 2 to DNA Media complex from step 1
and incubate. Step 4, FuGENE, DNA and Media Complex to 96 well plate: Add
FuGENE-DNA-Media complex from step 3 to each plate. Incubate.
Day 3: Dosing: Treatment preparation. Allow for transfection time.
Make a stock solution of the compounds in DMSO and vortex until all the compounds
have been dissolved. Further dilute in D-MEM (Low Glucose - without Phenol Red)
Add compounds in quadruplicate to give desired final volume then incubate.
Day 4: Luciferase Assay: Read the plates after drug treatment. Remove part of media
from all the wells and leave remainder. Add Steady-Glo Luciferase Reagent mixture/
wells and incubate. Count each well using a Luminescence counter, Top Count NXT
by Packard preferably set a delay between plates to reduce the background.
58

WO 2006/069153 PCT/DS2005/046360
The Caco-2 cell Co-transfection Assay:
The Caco-2 cell assay is an indicator for the undesirable condition of
hypercalcemia. This co-transfection assay is a surrogate assay for in vivo calcemic
activity of VDR ligands. It is desirable to have high EC50 values for a test compound
in this assay. The higher the EC50 values for a compound the less calcemic it will be
in vivo. Desired assay results are EC50 greater than or equal to 300 nM. Preferred
assay results are greater than 1000 nM.
Caco-2 cells, grown in phenol red free, DMEM (Invitrogen, Carlsbad, CA)
containing 10 % charcoal-stripped FBS (Hyclone, Logan, UT), are transfected with
Fugene 6 reagent (Roche Diagnostics, Indianapolis, IN). Cells (5000/well) are plated 18 h
before transfection in a 96 well plate. The cells are transfected with Gal4-responsive
reporter pFRLuc (150 ng, Stratagene, La Jolla CA) and the receptor expression vector
pGal4-VDR-LBD (10 ng), along with Fugene 6 reagent (0.2 μl/well). The DNA-Fugene
complex is formed by incubating the mixture for 30 m at room temperature. The cells are
transfected in triplicate for 5 h, and treated with various concentrations of VDR ligands
(from 0.01 nM to 10,000 nM concentration range) 18h post-transfection. The luciferase
activity is quantified using Steady-Glo reagent kit (Promega, Madison, WI) as per
manufacturer's specifications.
The OCN (osteocalcin) Promoter Assay
The OCN Promoter Assay is an indicator and marker for osteoporosis. Desired assay
results are EC50 less than or equal to 325 nM. Preferred assay results are less than 50
nM.
The activation of osteocalcin by VDR ligands is evaluated in a rat osteo blast-like
cell line RG-15 (ROS 17/2.8) stably expressing rat osteocalcin promoter fused with
luciferase reporter gene. The stable cell lines are established as reported before
(Activation of Osteocalcin Transcription involves interaction of protein kinase A- and
Protein kinase C-dependent pathways. Boguslawski, G., Hale, L. V., Yu, X.-P., Miles, R.
R., Onyia, J. E., Santerre R. R, Chandrasekhar, S. J Biol. Chem. 275, 999-100(3,2000).
Confluent RG-15 cells maintained in DMEM/F-12 medium (3:1) containing 5% FBS, 300
ug/ml G418 and at 37°C under 5% CO2/95% air atmosphere are trypsinized (0.25%
trypsin) and plated into white opaque 96-well cell culture plates (25000 cells/well). After
59

WO 2006/069153 PCT/DS2005/046360
24 hr, cells (in DMEM/F-12 medium + 2% FBS) are treated with various concentrations
of compounds, dissolved in DMSO. The final DMSO concentration remains at 0.01%
(v/v). After 48 hr treatment, the medium is removed, cells are lysed with 50 p.1 of lysis
buffer (From Luciferase reporter assay system, Roche Diagnostics, Indianapolis, IN) and
then assayed for luciferase activity using the Luciferase Reporter Gene Assay kit from
Boehringer Mannheim as per manufacturer's specifications.
The Mouse Hypercalcemia Assay
The Mouse Hypercalcemia Assay is a six day hypercalcemia test for toxiicity and
selectivity. Acceptable test results are levels greater than 30 μg/kg/day. Preferred assay
results are levels greater than 300 μg/kg/day.
Weanling, virus -antibody-free, five to six weeks old female DBF mice (Harlan,
Indianapolis, IN) are used for all the studies. Animals are allowed to acclimate to local
vivarium conditions for 2 days. Mice are maintained on a 12 hr light/dark cycle at 22°C
with ad lib access to food (TD 5001 with 1.2% Ca and 0.9% P, Teklad, Madison., WI) and
water. The animals then are divided into groups with 4-5 mice per group. Different
doses of test compounds prepared in 10% ethanol and 90% sesame oil, or in an aqueous
suspension of sodium lauryl sulfate and CMC (the latter formulation for acidic
compounds) are administered to mice orally via gavage for 6 days. la-25(OH)2D3
0.5μg/kg/d was also given to one group of mice as the positive control. Serum ionized
calcium is evaluated at 6 hours after the last dosing under isoflurane anesthesia by Ciba-
Corning Ca++/PH Analyzer, (Model 634, Chiron Diagnostics Corp., East Walpole, MA).
Raw data of group differences is assessed by analysis of variance (ANOVA) using
Fisher's protected least significant difference (PLSD) where the significance level was P<
0.05. The highest dose that did not cause hypercalcemia, as defined by the 97.5%
reference distribution of the control population, is considered "the no effect level".
The Keratinocvte Proliferation Assay
This Assay is indicative for the treatment of psoriasis. An acceptable test
result is IC50 value of less than or equal to 300 nM. Preferred assay results are IC50
values of less than 100 nM.
60

WO 2006/069153 PCT/DS2005/046360
KERtr cells (Human skin keratinocyte are transformed with a retrovirus vector,
obtained from ATCC, then are plated in 96-well flat-bottomed plates (3000 cells/well) in
100 μl keratinocyte serum free medium supplemented with bovine pituitary extract in the
absence of EGF (Life Technologies, Rockville, MD) and are incubated at 37°C for two
days. The cells are treated with various concentrations of VDR ligands (ten-fold serial
dilution from 10,000 nM to 0.1 nM in triplicate), dissolved in 100 ul keratinocyte serum
free medium supplemented with bovine pituitary extract in the absence of EGF and are
incubated at 37°C for 72 hr. BrdU (5-bromo-2'-deoxyuridine) incorporation is analyzed
as a measure of DNA replication (Cell proliferation ELISA kit, Roche Diagnostics,
Indianapolis, IN) and absorbance is measured at 405 ran. Potency values (IC50) values
were determined as the concentration (nM) of compound that elicited a half-maximal
response.
The IL-10 induction Assay
This is an in vitro efficacy assay for psoriasis, abscess and adhesion. Psoriasis
involves both keratinocytes and immune cells. IL-10 is a unique cytokine because it is
anti-inflammatory and immunosuppressive. This assay tells us whether a VDRM is able
to function as an agonist in PBMCs (primary blood mononuclear cells) or not. A lower
EC50 value is desirable in this assay since a compound with a lower EC50 value will be a
better agonist in PBMCs. An acceptable test result is an EC50 value of less man 200 nM.
Preferred assay results are EC50 values of less than 100 nM.
Isolation of peripheral blood mononuclear cells (PBMCs):
Collect 50 ml of human blood and dilute with media, RPMI-1640. Add diluted
blood to sterile tubes with ficol. Centrifuge the tubes. Discard the top layer and collect
the cells from middle layer. Divide all cells into four tubes and add media. Centrifuge.
Aspirate off media and resuspendthe cells. Collect all cells. Centrifuge at 1200 rpm for
10 m. Resuspend the cells in RPMI-1640 with 2% FBS and then count cells.
Stimulation of PBMC: Prepare TPA in DMSO. Dissolve PHA in water. Plate
TPA/PHA treated PBMCs in well plates. Incubate the cells.
61

WO 2006/069153 PCT/DS2005/046360
Treatment: Prepare all compound dilutions in plain RPMI- 1640 media. Add diluted
compound and incubate. Sample Collection and assay: Remove all the cells by
centrifugation and assay the supernatant for IL-10 by immunoassay using anti-human IL-
10 antibody coated beads, as described by the manufacturer (Linco Research Inc., St.
Charles, MO).
Other Compound Assay Standards
An alternative measure of the therapeutic index (bone efficacy vs Hypercalcemia) of
compounds of the invention for treatment of osteoporosis is a numerical ratio
calculated as follows:
Dose Threshold needed to induce hypercalcemia
divided by
Dose Threshold needed for bone efficacy
An alternative measure of the therapeutic index (in vivo keratinocyte proliferation vs.
hypercalcemia) of compounds of the invention for treatment of psoriasis is a
numerical ratio calculated as follows:
Dose Threshold needed to induce hypercalcemia
divided by
Dose Threshold needed to induce keratinocyte proliferation
For the above ratios, Dose Thresholds are determined from dose response curve data.
The CaTl (calcium transporter 1) Assay
The CaTl Assay is an indicator for the undesirable condition of
hypercalcemia. The higher the EC50 values for a compound the less calcemic it will
be in vivo. Desired assay results are EC50 greater than or equal to 500 nM. Preferred
assay results are greater than 1000 nM.
Human colon carcinoma, Caco-2 cells, maintained in DMEM (high glucose with
25 mM Hepes buffer; Invitrogen, Carlsbad, CA) supplemented with 10 % FBS
(Invitrogen, Carlsbad, CA), are plated at 5500 cell per well in a 96-well plate in a total
volume of 100 μI/well. The cells are kept in the 96-well plate for 6 days to differentiate
them to small intestinal cells that express the calcium transporter, CaTl. On day 3 after
plating, old media is removed and replaced with fresh media (150 μl/well). On day 6 the
62

WO 2006/069153 PCT/DS2005/046360
old media is removed and the cells are kept in treatment media (180 nl/well) that
contained 10 % charcoal strippedFBS (Hyclone, Logan, UT) in DMEM (low glucose,
without phenol red; Invitrogen, Carlsbad, CA). The cells are treated with various
concentrations of VDR ligands (from 0.01 nM to 10,000 nM concentration range)
prepared in treatment media (20 μl/well). Twenty hours post-treatment, total RNA is
prepared by RNeasy 96 method as described by the manufacturer (Qiagen, Valencia,
CA). The RNA is reverse transcribed and amplified for human CaTl and GAPDH
(control) messages by quantitative RT-PCR using ABI PRISM 7900HT Sequence
Detection System according to manufacturer's instructions (Applied Biosystems, Foster
City, CA). Optimized primer pairs and probes for human CaTl and GAPDH genes are
obtained commercially (Applied Biosystems, Foster City, CA). Each 20 |xl quantitative
RT-PCR reaction in a 384-well Taqman PCR plate consists of forward and reverse
primers (900 nM), Taqman probe (200 nM), total RNA (4 |xl form each well of the 96-
well culture plate) and 10 μl of Taqman Universal PCR Master Mix (Roche Diagnostics,
Indianapolis, IN). Reactions are incubated at 48°C for 30 m, followed by 10 m at 95°C
and subjected to 40 cycles of PCR (95°C for 15 seconds followed by 60°C for 1 m).
GAPDH is used as an internal control and its primer and probe set are obtained
commercially (Applied Biosystems, Foster City, CA).
63

1. A compound or a pharmaceutically acceptable salt or a prodrug derivative
thereof represented by Formula(L):

wherein
R and R' are independently C1-C5 alkyl, C1-C5 haloalkyl, or together R and R'
form a substituted or unsubstituted, saturated or unsaturated cycloalkyl ring having from 3
to 8 carbon atoms;
RP3 and RN are independently selected from hydrogen, halo, C1-C5 alkyl, C1-
C5 haloalkyl, -O-C1-C5 alkyl, -S-C1-C5 alkyl, -O-C1-C5 haloalkyl, -CN, -NO2,
acetyl, -S-C1-C5 haloalkyl, C2-C5 alkenyl, C3-C5 cycloalkyl, and C3-C5 cycloalkenyl;
RP is selected from: hydrogen, halo, C1-C5 alkyl, C1-C5 haloalkyl, -O-C1-C5
alkyl, -S-C1-C5 alkyl, -O-C1-C5 haloalkyl, -CN, -NO2, acetyl, -S-C1-C5 haloalkyl,
C2-C5 alkenyl, C3-C5 cycloalkyl, and C3-C5 cycloalkenyl;
(Lp1), (Lp2), and (LNP) are divalent linking groups independently selected from: a
bond, -(CH2)m-C(OH)-, -(CH2)m-O-, -(CH2)m-S-, -(CH2)m-S(O)-,
-(CH2)m-S(O)2-, -(CH2)m-N(R40)-, -(CH2)m-C(R40)(R41)-,
-(CH2)m-C(O)-, -N(R40)-C(O)-, -(CH2)m-CH=CH-, and -(CH2)m-OC-;
where m is 0-5;
R40 and R41 each is independently selected from: hydrogen, C1-C5; alkyl, C1-
C5 hydroxyalkyl, C1-C5 haloalkyl, C2-C5 alkenyl, C3-C5 cycloalkyl, C3-C5
cycloalkenyl;
64

Zp is selected from: branched C3-C5 alkyl, C3-C10 hydroxyalkyl, C3-C10
hydroxyalkenyl, C3-C10 hydroxyalkynyl, C3-C10 hydroxycycloalkyl, C4-C10 hydroxy
cycloalkenyl, and oxocycloalkyl;
ZNP is selected from: C1-C5 alkyl, C2-C5 alkenyl, C3-C5 cycloalkyl, C3-C5
cycloalkenyl, C1-C5 hydroxyalkyl, C1-C5 haloalkyl, C1-C5 alkylaryl, C1-C5
hydroxyalkylaryl, Co-C5 alkyl-CO2H, C0-C3 alkyl-cycloalkyl-CO2H, C0-C5
alkyl-N(R40)(R41), -X-(C,-C5 alkyl), -X-(C,-C5 alkenyl), -X-(C3-C5 cycloalkyl),
-X-(C3-C5 cycloalkenyl), -X-(C1-C5 haloalkyl), -X-(C1-C5 hydroxyalkyl), -X-(C,-C5
alkylaryl), -X(OC1-C5 alkyl), -XN(R40)(R41),
-XN(R40)aryl, -N(CH3)(OCH3), -N(OH)(CH3), -N(R42)-(C,-C5 alkyl)CO2H, -N(R42)-
(C1-C5 alkyl)C(O)(C,-C5 alkyl), -N(R42)-(C,-C5 alkyl)C(O)(OCi-C5 alkyl), -N(R42)-
SO2-(C1-C5 alkyl), -NR(42)-S(O)-(C1-C5 alkyl), -P(O)-(OC1-C5 alkyl)2, heteroalkyl,
heteroaryl, and -N=C(R40)N(R40)(R41);
R42 is selected from: H, C1-C3 alkyl, and C,-C3 haloalkyl; and
X is selected from: O, C(O), C(S), S(O), and SO2;
provided that -(LNP)-ZNP is substituted at either the 12 or 13 position of the naphthalene
ring.
2. A compound of Claim 1, or a pharmaceutically acceptable salt thereof,
wherein
R and R' are independently methyl or ethyl;
RP is hydrogen or methyl;
RP3 and RN are independently hydrogen, methyl, ethyl, -O-methyl, or cyclopropyl;
(LPI) is a bond;
(LP2) is a bond, -CH2-, -CH(OH)-, or-C(Me)OH-;
(LNP) is a bond, -C(O)-, -C(O)NH-, or -C(O)N(Me)-;
Zp is selected from the group consisting of: 1,1-dimethylethyl, 1-
hydroxycyclopentyl, ,1-hydroxycyclohexyl, 3-ethyl-3-hydroxypentyl, 3-ethyl-3-
hydroxypentenyl, and 3-ethyl-3-hydroxypentynyl;
ZNP is -CO2H,- -CO2(R40), -N(R40)(R41), -NH-C(Me)(OH)-C(O)OH,
65

66
-C(O)NMe-CH2-C(O)OH, -C(O)NMe-CH2-C(O)OMe, -C(O)NMe-CH2-C(O)OEt,
-C(O)NMe-CH2-C(O)OiPr, -C(O)NMe-CH2-C(O)tBu, -cyclopropyl-C(O)OH,
-cyclobutyl-C(O)OH, -C(O)NMe-C(Me)2-C(O)OH,
-C(O)N(R40)S(O)(R42), -C(O)N(R40)SO2R42, -C(O)-N(R40)-5-tetrazolyl,
-C(O)N(R40)-(Ci-C5 alkyl)-S(O)R42, -C(O)N(R40)-(C,-C5 alkyl)-S(O)2R42, and
-CH2CO2H.



67

wherein Rl is H, methyl, or ethyl; R2 is H or methyl R3 is H ,methyl, or ethyl, and R4 is
H or methyl.
4. The compound of claim 3 represented by formulae (Cl) to (C8) or a
pharmaceutically acceptable salt or prodrug derivative thereof: where Rl is a methyl, or
ethyl; and R2 is H or methyl.
5. The compound of claim 3 represented by the structural Formula(C2) or a
pharmaceutically acceptable salt thereof.
6. A compound according to claim 3 represented by the structural
Formula(Cl) or a pharmaceutically acceptable salt thereof.
7. A prodrug derivative of the compound of any of claims 1 to 3 wherein the
prodrug is a methyl ester; ethyl ester; N,N-diethylglycolamido ester; or morpholinylethyl
ester.
8. A salt derivative of the compound of any of claims 1 to 5 wherein the salt is
sodium or potassium.
9. A pharmaceutical formulation comprising the compound of any of claims 1
to 7 with a pharmaceutically acceptable carrier or diluent.
10. A formulation for treating osteoporosis comprising:
a compound of Formula I of any of claims 1 to 8;
one or more co-agents selected from the group consisting of: estrogens,
androgens, calcium supplements, vitamin D metabolites, thiazide diuretics, calcitonin,
bisphosphonates, SERMS, fluorides; and
optionally, a carrier or diluent.
68

11. The formulation of claim 9 wherein the weight ratio of a compound of
Formula 1 and the one or more co-agents is from 10:1 to 1:1000.
12. A formulation according to claim 9 for treating psoriais comprising:
a compound of Formula 1 of any of claims 1 to 8;
one or more co-agents selected from the group consisting of: topical
glucocorticoids , salicylic acid, crude coal tar; and
optionally, a carrier or diluent.
13. The formulation of claim 12 wherein the weight ratio of Formula I and the
one or more co-agents is from 1:10 to 1:100000.
14. Use of compound of Formula 1 in any of claims 1-8, or a pharmaceutical
acceptable salt thereof, in the manufacture of a medicament for the treatment of
osteoporous.
15. Use of a compound of Formula 1 according to any one of claims 1 to 8, or a
pharmaceutical acceptable salt thereof, for the manufacture of a medicament for the
treatment of Acne, Actinic keratosis, Alopecia , Alzheimer's disease, Bone maintenance in
zero gravity, Bone fracture healing, Breast cancer, Chemoprovention of Cancer, Crohn's
disease, Colon cancer, Type 1 diabetes, Host-graft rejection, Hypercalcemia , Type II
diabetes, Leukemia, Multiple sclerosis, Myelodysplastic syndrome, Insufficient sebum
secretion, Osteomalacia, Osteoporosis, Insufficient dermal firmness, Insufficient dermal
hydration, Psoriatic arthritis, Prostate cancer, Psoriasis, Renal osteodystrophy, Rheumatoid
arthritis, Scleroderma, Skin cancer, Systemic lupus erythematosus, Skin cell damage from
mustard vesicants, Ulcerative colitis, Vitiligo, or Wrinkles.
16. A compound as claimed in any one of Claims 1 to 8, or a pharmaceutical
acceptable salt thereof, for use as a medicament.
69

70
17. A compound or a pharmaceutically acceptable salt or a prodrug derivative, a
pharmaceutical formulation, a formulation for treating osteoporosis and use of a
compound of Formula 1 are substantially described herein with reference to foregoing
examples and illustrations.

The present invention relates to novel, non-secosteroidal, phenyl-naphthalene compounds of Formula (I): wherein R, Rl, RP, ZP, LP1, LP2 LNP, RP3, RN, and ZNP are defined herein, their preparation, pharmaceutical compositions, and methods of use.